1	Comparative Effective	ness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among
2	Older Adults: Systemat	tic Literature Review and Meta-Analysis Using the GRADE
3	Framework	
4	Sushma Kavikondala, Ph	D, ¹ Katrin Haeussler, PhD, MSc, ² Xuan Wang, MD, MSc, ³ Mary T.
5	Bausch-Jurken, PhD, MS	S, ⁴ Maria Nassim, MSc, ² Nitendra Kumar Mishra, MS, ⁵ Mia
6	Malmenäs, MSc, ³ Pawar	a Sharma, MSc, ⁶ Nicolas Van de Velde, PhD, ⁴ Nathan Green, PhD, ⁷
7	Ekkehard Beck, PhD ⁴	
8	¹ ICON plc, Toronto, ON	, Canada; ² ICON plc, Langen, Germany; ³ ICON plc, Stockholm,
9	Sweden; ⁴ Moderna, Inc.,	Cambridge, MA, USA; ⁵ ICON plc, Bengaluru, India; ⁶ ICON plc,
10	London, UK; ⁷ University	V College London, London, UK
11	Corresponding Author:	Ekkehard Beck, PhD
12		Moderna, Inc.
13		200 Technology Square
14		Cambridge, MA, 02139, USA
15		Email: Ekkehard.Beck@modernatx.com
16		Phone: +49 151 68557928
17	Running title:	Comparative Real-World Effectiveness of COVID-19 Vaccines in
18		Older Adults
19	ABSTRACT	
19		
20	Background: The mRN	A vaccines mRNA-1273 and BNT162b2 demonstrated high efficacy
21	against SARS-CoV-2 inf	Section in phase 3 clinical trials, including among older adults. To
22	inform COVID-19 vacci	ne selection, this systematic literature review (SLR) and meta-

analysis assessed the comparative effectiveness of mRNA-1273 versus BNT162b2 in older
adults.

25	Methods: We systematically searched for relevant studies reporting COVID-19 outcomes
26	with mRNA vaccines in older adults aged ≥ 50 years by first cross-checking relevant
27	published SLRs. Based on the cutoff date from a previous similar SLR, we then searched the
28	WHO COVID-19 Research Database for relevant articles published between April 9, 2022
29	and June 2, 2023. Outcomes of interest were SARS-CoV-2 infection, symptomatic SARS-
30	CoV-2 infection, severe SARS-CoV-2 infection, COVID-19-related hospitalization, and
31	COVID-19-related death following ≥ 2 vaccine doses. Random-effects meta-analysis models
32	were used to pool risk ratios (RRs) across studies. Heterogeneity was evaluated using chi-
33	squared testing. Evidence certainty was assessed per GRADE framework.
34	Results: 24 non-randomized real-world studies reporting clinical outcomes with mRNA
35	vaccines in individuals aged \geq 50 years were included in the meta-analysis. Vaccination with
36	mRNA-1273 was associated with significantly lower risk of SARS-CoV-2 infection (RR 0.72
37	[95% confidence interval (CI) 0.64–0.80]), symptomatic SARS-CoV-2 infection (RR 0.72
38	[95% CI 0.62–0.83]), severe SARS-CoV-2 infection (RR 0.67 [95% CI 0.57–0.78]), COVID-
39	
	19-related hospitalization (RR 0.65 [95% CI 0.53-0.79]) and COVID-19-related death (RR
40	0.80 [95% CI 0.64–0.99]) compared with BNT162b2. There was considerable heterogeneity
40 41	
	0.80 [95% CI 0.64–0.99]) compared with BNT162b2. There was considerable heterogeneity
41	0.80 [95% CI 0.64–0.99]) compared with BNT162b2. There was considerable heterogeneity between studies for all outcomes (I^2 >75%) except death (I^2 =0%). Multiple subgroup and

- 45 **Conclusion:** Meta-analysis of 24 observational studies demonstrated significantly lower risk
- 46 of asymptomatic, symptomatic, and severe infections; hospitalizations; and deaths with the
- 47 mRNA-1273 versus BNT162b2 vaccine in older adults aged \geq 50 years.
- 48 Keywords: BNT162b2; COVID-19; effectiveness; mRNA-1273; mRNA vaccine; older
- 49 adults; SARS-CoV-2; severe acute respiratory syndrome coronavirus 2

50 SUMMARY POINTS

51	•	The COVID-19 pandemic has disproportionately affected older adults, as this population
52		is generally more susceptible to infection and severe outcomes due to immune senescence
53		and underlying comorbidities.
54	•	The 2 available mRNA vaccines mRNA-1273 and BNT162b2 demonstrated high efficacy
55		against SARS-CoV-2 infection in phase 3 clinical trials, including among older adults.
56	•	To inform COVID-19 vaccine selection, this systematic literature review and meta-
57		analysis assessed the comparative effectiveness of mRNA-1273 versus BNT162b2 among
58		older adults in real-world settings.
59	•	Vaccination with homologous primary or booster mRNA-1273 was associated with
60		significantly lower risk of infection (including asymptomatic, symptomatic, and severe
61		infections), hospitalization, and death due to COVID-19 than vaccination with BNT162b2
62		in older adults aged \geq 50 years.

64 INTRODUCTION

As of October 2023, the global coronavirus disease 2019 (COVID-19) pandemic has resulted 65 66 in more than 771.4 million reported infections and over 6.9 million deaths due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1). COVID-19 has disproportionately 67 affected older adults (2, 3, 4, 5). Worldwide, older adults aged ≥ 60 years accounted for 80% 68 69 of COVID-19-associated deaths reported to the World Health Organization (WHO) via 70 detailed weekly surveillance from January 2020 to December 2021, and were estimated to account for 82% of deaths based on the WHO excess mortality model (4). Immune 71 72 senescence and underlying comorbidities make older adults generally more susceptible to COVID-19 and associated severe outcomes. Several studies have identified older age as a 73 primary risk factor for severe illness with COVID-19 (6, 7, 8), with one study demonstrating 74 75 similar performance between a risk score that was based on age alone versus a validated risk score incorporating the effects of multiple underlying comorbidities (POINTED score) (9). 76 Importantly, the WHO has identified older adults (commonly defined by age cutoffs of 50 to 77 60 years, depending on the country) as a high-priority group for COVID-19 vaccination (10), 78 79 and many countries have prioritized vaccination of the older population (9).

80 A previous meta-analysis of 32 studies in older adults aged \geq 55 years found that vaccination with either one of the 2 vaccines employing novel messenger ribonucleic acid (mRNA) 81 82 technology provided the highest protection against COVID-19 compared with other vaccine types (11). The mRNA vaccines were developed and granted emergency use authorization in 83 late 2020 to globally mitigate the spread of SARS-CoV-2: mRNA-1273 (Spikevax[®]; 84 85 Moderna, Inc., Cambridge, MA, USA) (12) and BNT162b2 (Comirnaty®; Pfizer/BioNTech, New York, NY, USA/Mainz, Germany) (13). Phase 3 trials of these vaccines demonstrated 86 high vaccine efficacy against SARS-CoV-2 infection when administered as 2-dose regimens 87 88 (94.1% and 95.0% effectiveness with mRNA-1273 and BNT162b2, respectively) (14, 15),

with subgroup analyses also confirming high vaccine efficacy in older participants (aged ≥65
years) (14, 15).

91	Although both mRNA-1273 and BNT162b2 are based on mRNA technology, their
92	formulations differ. For example, the mRNA-1273 vaccine contains more active ingredient
93	(100 μ g of mRNA for primary; 50 μ g for booster) than the BNT162b2 vaccine (30 μ g of
94	mRNA for both primary and booster) (12, 13, 16, 17) and uses a different lipid nanoparticle
95	delivery system (18, 19, 20). As shown with other respiratory vaccines (21, 22), and as
96	demonstrated in immunocompromised individuals (23), these differences may impact vaccine
97	effectiveness in older adults. Thus, to inform COVID-19 vaccine selection and policy
98	decision-making in the absence of head-to-head comparisons of the mRNA-1273 and
99	BNT162b2 vaccines in randomized controlled trials (RCTs), there remains a need to
100	synthesize evidence across real-world studies to provide robust information about the
101	comparative effectiveness of the two mRNA vaccines among older adults.
102	We performed a systematic literature review and pairwise meta-analysis to compare the
103	effectiveness of mRNA-1273 versus BNT162b2 in older adults. Our analysis followed the
104	Grading of Recommendations, Assessment, Development and Evaluations (GRADE)
105	framework (24) used by national immunization advisory groups when developing
106	recommendations (25). The question addressed in the present research was 'Is mRNA-1273
107	more effective than BNT162b2 at preventing SARS-CoV-2 infections and COVID-19-related
108	hospitalizations and deaths in older adults aged ≥ 50 years?'.

109 METHODS

110 Search strategy and study selection

111 This systematic literature review and meta-analysis is registered in Prospero (CRD42023443149) and was conducted in accordance with the Preferred Reporting Items for 112 Systematic Reviews and Meta-Analyses 2020 framework (26). Studies were identified using 113 a 2-step search procedure. First, the WHO COVID-19 Research Database was searched to 114 identify systematic literature reviews on COVID-19 vaccination in older adults aged \geq 50 115 years published between March 2020 and 19 April 2023. Sixteen of 67 systematic reviews 116 117 identified were relevant (Supplemental Table S1) and were cross-checked for articles to be included in abstract screening and full-text assessment. One prior systematic review 118 119 identified had similar objectives to the current study (11) and all studies included in this prior review were included for full-text assessment. A total of 243 studies for full-text screening 120 were identified from this first step. The main search was then conducted in the WHO 121 122 COVID-19 Research Database to identify relevant studies published since the prior similar 123 systematic review (11), which included studies from database inception through 9 April 2022 to 2 June 2023. Notably, although the WHO COVID-19 Research Database remains 124 125 searchable, updates ceased in June 2023 (27), thus content spans March 2020 through June 2023. Databases searched include MEDLINE/PubMed, International Clinical Trials Registry 126 Platform, Embase, EuropePMC, medRxiv, Web of Science, ProQuest Central, Academic 127 Search Complete, Scopus, and COVIDWHO. The main database search identified an 128 129 additional 1012 studies for full-text screening. The main search strategy is summarized in 130 Supplemental Table S2.

RCTs, observational studies, or any real-world evidence published as full-text manuscripts,
letters, commentaries, abstracts, or posters were included if they reported prespecified

COVID-19 outcomes (described below) in older adults aged ≥50 years who received mRNA-133 1273 or BNT162b2 within the same study (studies with $\leq 10\%$ of the study population aged 134 135 \leq 50 years included). Studies could include participants who had comorbidities, and those who were immunocompetent or defined as clinically extremely vulnerable (CEV) with 136 conditions in CEV group 3, as categorized by Canadian Health Services (28) (studies with 137 $\leq 10\%$ of participants with CEV group 1 and 2 conditions were included). Diabetes was 138 139 considered a CEV group 3 condition regardless of whether the patient was being treated with 140 insulin. Only studies reporting the outcomes of interest for participants who received ≥ 2 141 vaccine doses were included and wherever available three-dose data was considered 142 primarily. If a study did not report the outcomes for participants who received three doses, then two-dose or four-dose data was considered. Only homologous dose series (≥2 doses of 143 144 mRNA-1273 or ≥ 2 doses BNT162b2) were included in analysis.

Outcomes of interest were vaccine efficacy or effectiveness against SARS-CoV-2 infection 145 146 (defined as asymptomatic or symptomatic infection with positive test or a COVID-19 147 diagnosis code [U07.1]), laboratory-confirmed symptomatic SARS-CoV-2 infection (defined as positive test with symptoms including but not limited to fever, cough, shortness of breath 148 149 and sudden onset of anosmia/ageusia; in some countries, runny nose was also included in the case definition), severe SARS-CoV-2 infection (defined specifically as severe infection or as 150 hospitalization or death, as reported in the study; primarily defined by severe infection, 151 followed by hospitalization and lastly by death if data on multiple endpoints were available), 152 153 COVID-19-related hospitalization (defined as intubation, hospitalization, or admission to 154 intensive care unit with positive test for SARS-CoV-2 infection within 5 days before to 28 days from admission; cases with information on intubation but not hospitalization were 155 156 assumed to be hospitalized), or COVID-19-related death (defined as deaths occurring after a 157 positive test for SARS-CoV-2 infection without previously declared recovery or another clear

cause of death reported). A positive SARS-CoV-2 test could be based on any of the following 158 methods, as reported by individual studies: reverse transcription polymerase chain reaction 159 160 (PCR), rapid antigen test, or dried blood spot seropositivity for anti-nucleocapsid immunoglobulin G antibodies by validated enzyme-linked immunosorbent assay. Infections 161 were considered if they occurred \geq 7 days after the last vaccination. Only those studies that 162 163 reported the following data were included in the meta-analysis: number of events and sample 164 size per arm; or vaccine effectiveness (VE) per arm and subgroup derived as 1-risk ratio (RR), 1-odds ratio (OR), 1-hazard ratio (HR), or 1-incidence rate ratio (IRR). For the 165 166 analyses of VE, if only VE data and total numbers of participants by vaccine arm were available, then the weighted average VE for all age groups among individuals aged \geq 50 years 167 was computed. Weighted average was calculated as the sum of the VE in all age groups in a 168 169 vaccine arm divided by the total number of participants in that arm. If only VE data were 170 available without participant numbers by vaccine arm, then VE in the age group that most closely matched the data within the studies in the meta-analysis was selected. 171

172 Studies in pregnant women, current or former smokers, and physically inactive participants; studies including only immunocompromised individuals with conditions within CEV groups 173 174 1 and 2; and studies with only safety and/or immunogenicity outcomes were excluded. The population, exposure, comparison, and outcomes used in the systematic literature review are 175 summarized in Supplemental Table S3. Two independent reviewers selected studies using a 176 2-level approach; discrepancies were resolved by consensus or by a third reviewer. In level 1, 177 178 titles and abstracts were screened against inclusion criteria; then in level 2, articles not 179 excluded at level 1 underwent full-text screening against the selection criteria.

180 Data extraction and quality assessment

Study design details, baseline characteristics of study participants, vaccine received and dosing details, and vaccine efficacy/effectiveness outcomes were extracted from the selected studies. Risk of bias was assessed using the Newcastle-Ottawa Scale (29) for observational studies. The certainty of evidence was evaluated based on GRADE criteria (24, 25).

185 Statistical analysis

Random-effects meta-analysis models were used to pool RRs and to estimate absolute effects 186 as risk difference (RD) per 100,000 individuals across the included studies, comparing 187 188 mRNA-1273 to BNT162b2. The inverse variance method was applied for the random effects models (30). Details regarding methodology of the analyses are included in Appendix 1. 189 190 Briefly, a standard pairwise meta-analysis was conducted using RRs instead of number of 191 events and sample size per arm as the data input. However, due to differences in how 192 outcomes were reported across studies, a conversion approach (31, 32, 33) was implemented. 193 For studies that reported the number of events and sample size per arm, unadjusted RRs were 194 estimated straightforwardly. For studies that exclusively reported VE, instead of number of events and sample size per arm, RR was either estimated as "1–VE" (for studies reporting VE 195 196 as 1–RR) or estimated from VE through optimal approximate conversions of contrast-based 197 data (Supplemental Figure S1). As a sensitivity analysis, a second-order meta-analysis 198 approach was implemented to avoid the assumptions based on converting contrast-based data in the conversion approach. With this approach, data from studies reporting number of events 199 200 and sample size were pooled in one meta-analysis, and data from studies reporting only VE 201 were pooled in a second meta-analysis (i.e., without distinction as to how VE was estimated 202 and without any conversion). In the second-order meta-analysis, the pooled results from these 203 separate meta-analyses on RRs informed the analysis, resulting in the final RR estimate.

Absolute effects (RD) cannot be reliably estimated using this second-order approach, so thismethod was used only for analysis of RR.

206	As additional sensitivity analyses, outcomes were assessed in the following subgroups:
207	individuals aged \geq 65 years; individuals aged \geq 75 years; individuals who received exclusively
208	three doses of the same vaccine; individuals aged \geq 50 years, excluding those with disease
209	conditions categorized in CEV groups 1 or 2; individuals infected with the SARS-CoV-2
210	Delta variant (ie, dominant variant during study time period); and excluding those studies that
211	reported only VE.
212	Publication bias was assessed by visual examination of funnel plots and Egger's regression
213	test for asymmetry (34, 35). Heterogeneity across studies was evaluated using chi-squared
214	testing (36), with the percentage of variation across studies estimated using the I^2 statistic
215	(scale of 0%–100%, with 0% meaning no evidence of heterogeneity; see Appendix 1).
216	Results were summarized in forest plots to display the effect estimates with 95% CIs for the
217	individual studies and the pooled estimate of the meta-analysis. The meta-analyses were
218	conducted in R (v4.3.1), using the meta (37) and metafor (38) packages.

220 **RESULTS**

221 Search results and included studies

In total, 1255 abstracts identified from either the 16 relevant SLRs that were crosschecked

223 (n=243) or the main search in the WHO COVID-19 database (n=1012) were screened for

inclusion (Figure 1). Of these, 25 studies (all non-randomized) reported results for the

clinical outcomes of interest in individuals aged \geq 50 years, 24 of which were included in the

226 meta-analysis (one study (39) was excluded because it reported only RR thus did not meet the

227 prespecified criterion of reporting number of events and sample size or VE).

228 Characteristics of each of the studies included in the meta-analysis are summarized in Table

1. Of the 24 studies, 1 was industry-sponsored. Overall, the studies included >3.9 million

older adults (aged \geq 50 years) vaccinated with mRNA-1273 and >5.2 million vaccinated with

BNT162b2. Most studies involved North American (Canada, n=2 (40, 41); United States,

232 n=11 (42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)) or European (Belgium, n=1 (53); Greece,

233 n=1 (54); Hungary, n=2 (55, 56); Norway, n=1 (57); Netherlands, n=1 (58); Spain, n=2 (59,

60); multiple countries, n=1 (61)) populations. Although most studies included general

population samples, two were restricted to nursing home or retirement home residents (40,

43) and two were restricted to Veteran's Affairs populations in the United States (42, 44).

237 The majority of studies specified the Delta variant as the SARS-CoV-2 variant of concern

238 (42, 43, 45, 46, 47, 48, 50, 51, 53, 54, 56, 57, 58, 60, 61); 5 studies specified the Alpha

239 variant (46, 49, 53, 54, 55) and 4 specified the Omicron variant (40, 41, 50, 53). Some studies

240 with longer follow-up periods collected data during multiple COVID-19 seasons, therefore

- 241 reported data on multiple variants, either not further specified or in separate subgroups. We
- conducted a subgroup analysis in patients infected with the Delta variant due to the large
- number of available studies; subgroup analysis for other variants was deemed unfeasible due

to sparse data. In the majority of studies, positivity for SARS-CoV-2 infection was

245 determined using PCR or an antigen test; however, four studies did not specify the testing

246 method (44, 45, 47, 51) and one study used a nasopharyngeal PCR test and/or circulating

247 antinucleocapsid IgG antibodies (40).

Based on the risk of bias assessment for nonrandomized studies, most of the studies included
in the meta-analysis had no serious risk of bias; however there was serious risk of bias in four
studies (40, 45, 54, 59), and risk of bias was not estimable for one study (50) (Supplemental
Table S4).

252 SARS-CoV-2 infection

In meta-analysis of 22 studies reporting the outcome of SARS-CoV-2 infection in older 253 254 adults aged \geq 50 years, vaccination with mRNA-1273 was associated with significantly lower risk of SARS-CoV-2 infection compared with vaccination with BNT162b2 (RR 0.72 [95% 255 CI 0.64–0.80]; Table 2 and Figures 2 and 3). The RD was estimated as 442 fewer (95% CI 256 570 fewer to 313 fewer) SARS-CoV-2 infections per 100,000 people vaccinated. There was 257 considerable heterogeneity between the studies (RR $I^2=94.4\%$; RD, $I^2=98.4\%$). The certainty 258 259 of evidence was graded as type 4 (very low) due to imprecision and indirectness resulting 260 from the varying outcome definitions used for infection and inclusion of non-randomized studies (Table 2). In a sensitivity analysis using the second-order methodological approach, 261 262 vaccination with mRNA-1273 was associated with significantly fewer SARS-CoV-2 infections compared with BNT162b2 (RR 0.72 [95% CI 0.62–0.85]; I²=0%), consistent with 263 the base case analysis (Figure 4A and Supplemental Figure S2A). 264

In a subgroup analysis of 10 studies reporting the outcome of SARS-CoV-2 infection in

adults aged \geq 65 years, mRNA-1273 vaccination was also associated with significantly fewer

infections compared with BNT162b2 vaccination (RR 0.74 [95% CI 0.62–0.88]; RD 216

fewer cases per 100,000 vaccinated [95% CI 333 fewer to 100 fewer]; Table 3, Figure 4B 268 and **Supplemental Figure S3A**). Subgroup analysis of seven studies reporting this outcome 269 in individuals aged \geq 50 years who received exclusively three vaccine doses also found that 270 mRNA-1273 was associated with fewer infections versus BNT162b2 (RR 0.64 [95% CI 271 0.54-0.74]; RD 1098 fewer cases per 100,000 vaccinated [95% CI 1535 fewer to 661 fewer; 272 Table 3, Figure 4C and Supplemental Figure S4A). As in the overall population analysis, 273 274 the certainty of evidence in these two subgroups was graded as type 4 (very low) due to imprecision and varying outcome definitions (Table 3), and there was considerable 275 276 heterogeneity between studies (RR I²=89.5% for the \geq 65 years of age subgroup; I²=80.8% for the 3-dose subgroup). Additional subgroup analyses in older adults aged \geq 75 years; in older 277 adults aged \geq 50 years, excluding individuals with CEV group 1 and 2 conditions; in older 278 279 adults aged \geq 50 years infected with the Delta variant; and excluding those studies that only included VE data were generally consistent with the findings from the overall meta-analysis 280 (Supplemental Figures S5A, S6A, S7A, and S8A). 281

282 Laboratory-confirmed symptomatic SARS-CoV-2 infection

Five studies were included in the meta-analysis of laboratory-confirmed symptomatic SARS-283 284 CoV-2 infection in individuals aged \geq 50 years (**Table 2**). Vaccination with mRNA-1273 was associated with significantly fewer SARS-CoV-2 symptomatic infections versus vaccination 285 with BNT162b2 (RR 0.72 [95% CI 0.62–0.83; Figure 2 and 3). The RD was estimated as 286 609 fewer symptomatic infections per 100,000 individuals vaccinated (95% CI 980 fewer to 287 288 238 fewer cases). Heterogeneity between studies was also considerable for this outcome (RR I^2 =75.1%; RD I^2 =96.2%). The certainty of evidence was graded as type 3 (low) due to 289 290 imprecision, with a lower grading assigned due to inclusion of non-randomized studies 291 (Table 2). Possible publication bias was noted for this outcome based on Egger's regression 292 test (P < 0.05) (Supplemental Figure S9B). Because no VE data were used in the base case

- meta-analysis of symptomatic SARS-CoV-2 infections, no conversion was necessary.
 Therefore, results from the second-order methodological approach were identical to the base
- case results presented in **Figure 2** and **3**.
- Subgroup analysis based on two studies in individuals aged ≥ 65 years also found 296 significantly reduced risk of symptomatic SARS-CoV-2 infections with mRNA-1273 versus 297 BNT162b2 vaccination (RR 0.74 [95% CI 0.56-0.97]; RD 3,030 fewer cases per 100,000 298 vaccinated [95% CI 8,844 fewer to 2,784 more cases]; Table 3, Figure 4B and 299 Supplemental Figure S3B). Similarly, in meta-analysis of three studies that included 300 301 individuals aged >50 years who received exclusively three doses of vaccine, mRNA-1273 was associated with lower risk of symptomatic infections compared with BNT162b2 (RR 302 0.74 [95% CI 0.61–0.90]; RD 114 fewer cases per 100,000 individuals vaccinated [95% CI 303 304 338 fewer to 111 more]; Table 3, Figure 4C, Supplemental Figure S4B). As in the overall meta-analysis, heterogeneity between studies was considerable for these subgroups (RR 305 306 I^2 =90.8% and 79.0%, respectively). The certainty of evidence was graded as type 4 (very 307 low) for both subgroups (Table 3). Results of additional subgroup analyses in adults aged \geq 75 years; adults aged \geq 50 years, excluding individuals with CEV group 1 and 2 conditions; 308 309 and adults aged \geq 50 years infected with the Delta variant were generally consistent with the findings from the overall meta-analysis (Supplemental Figures S5B, S6B, and S7B). There 310 311 were no studies evaluating the outcome of lab-confirmed symptomatic SARS-CoV-2 312 infection that exclusively reported VE data.
- 313 Severe SARS-CoV-2 infection
- Based on meta-analysis of 12 studies, vaccination with mRNA-1273 was associated with
- 315 significantly fewer severe SARS-CoV-2 infections compared with vaccination with
- 316 BNT162b2 (RR 0.67 [95% CI 0.57–0.78]; **Table 2** and **Figure 2** and **3**). This result

317 corresponds to an estimated RD of 20 fewer severe infections per 100,000 individuals vaccinated with mRNA-1273 versus BNT162b2 (95% CI 29 fewer to 11 fewer cases). There 318 was considerable heterogeneity across studies for this outcome (RR $I^2=78.3\%$; RD 319 I^2 =86.1%). Evidence certainty was graded as type 4 (very low) due to imprecision and 320 varying definitions used for severe infection (defined as severe infection, or hospitalization, 321 or death; Table 2). Possible publication bias was noted for this outcome based on Egger's 322 323 regression test (P < 0.05; Supplemental Figure S9C). Consistent with the findings from the base case analysis, sensitivity analysis using the second-order methodological approach also 324 325 found that vaccination with mRNA-1273 was associated with significantly fewer severe SARS-CoV-2 infections compared with vaccination with BNT162b2 in older adults aged \geq 50 326 years (RR 0.66 [95% CI 0.59–0.75]; Figure 4A and Supplemental Figure S2B). 327

In subgroup analyses, mRNA-1273 was associated with significantly fewer severe SARSCoV-2 infections compared with vaccination with BNT162b2 in older adults aged ≥65 years
(eight studies; RR 0.65 [95% CI: 0.51–0.83]; RD 24 fewer severe infections per 100,000

received exclusively three vaccine doses (four studies; RR 0.62 [95% CI 0.44–0.88]; RD 10

individuals vaccinated [95% CI 41 fewer to 7 fewer]) and in adults aged \geq 50 years who

fewer severe infections per 100,000 individuals vaccinated [95% CI 16 fewer to 3 fewer];

Table 3, Figure 4B and 4C, and Supplemental Figure S3C and S4C). There was

substantial heterogeneity across studies for both subgroups (RR I^2 =63.5% and 60.4%,

respectively). Evidence certainty was graded as type 4 (very low; **Table 3**). Similar to the

findings from the overall meta-analysis, mRNA-1273 was associated with reduced risk of

severe SARS-CoV-2 infection in additional subgroup analyses of individuals \geq 75 years of

age, individuals (aged \geq 50 years) without CEV group 1 or 2 conditions, individuals (aged

 ≥ 50 years) infected with the Delta variant, and in the subgroup excluding those studies that

only included VE data (Supplemental Figures S5C, S6C, S7C, and S8B).

342 Hospitalization due to COVID-19

Based on a meta-analysis of eight studies, vaccination with mRNA-1273 was associated with 343 significantly lower risk of hospitalization due to COVID-19 in individuals aged \geq 50 years 344 compared with vaccination with BNT162b2 (RR 0.65 [95% CI 0.53-0.79]; Table 2 and 345 Figure 2 and 3). The estimated RD was 23 fewer COVID-19 hospitalizations per 100,000 346 individuals vaccinated (95% CI 34 fewer to 12 fewer). Heterogeneity across studies was 347 considerable (RR I^2 =85.4%; RD I^2 =90.3%). The certainty of evidence grade was type 3 (low) 348 for this outcome, due to imprecision and inclusion of non-randomized studies (Table 2). The 349 350 sensitivity analysis using the second-order methodological approach found that vaccination with mRNA-1273 was associated with significantly fewer COVID-19-related 351 hospitalizations compared with vaccination with BNT162b2 (RR 0.63 [95% CI 0.57-0.70]), 352 consistent with the base case analysis (Figure 4A and Supplemental Figure S2C). 353 Based on seven studies of COVID-19-related hospitalization in the subgroup of older adults 354 355 aged \geq 65 years, vaccination with mRNA-1273 was associated with significantly reduced risk of hospitalization compared with vaccination with BNT162b2 (RR 0.69 [95% CI 0.53–0.89]; 356 RD 82 fewer hospitalizations per 100,000 individuals vaccinated [95% CI 134 fewer to 29 357 358 fewer]; Table 3 and Figure 4B and Supplemental Figure S3D). As in the overall metaanalysis, there was considerable heterogeneity across studies (RR $I^2=72.0\%$), and the 359 evidence certainty was graded as type 3 (low; Table 3). Vaccination with mRNA-1273 was 360 also associated with significantly reduced risk of hospitalization compared with vaccination 361 362 with BNT162b2 among individuals aged \geq 50 years who received three vaccine doses based 363 on meta-analysis of three studies (RR 0.55 [95% CI 0.37–0.82]; RD 11 fewer hospitalizations per 100,000 individuals vaccinated [95% CI 18 fewer to 3 fewer]; Table 3 and Figure 4C 364 365 and Supplemental Figure S4D). There was moderate heterogeneity across studies (RR 366 I^2 =47.5%), and the evidence certainty was graded as type 4 (very low; **Table 3**). Additional

subgroup analyses in adults aged \geq 75 years; adults aged \geq 50 years, excluding individuals with CEV group 1 and 2 conditions; adults aged \geq 50 years infected with the Delta variant; and excluding those studies that only included VE data were generally consistent with the findings from the overall meta-analysis (**Supplemental Figures S5D, S6D, S7D, and S8C**).

371 Death due to COVID-19

372 In meta-analysis of seven studies reporting mortality in individuals aged \geq 50 years,

373 vaccination with mRNA-1273 was associated with significantly lower risk of COVID-19-

related death compared with vaccination with BNT162b2 (RR 0.80 [95% CI 0.64–0.99]). The

estimated RD was 2 fewer deaths per 100,000 people vaccinated (95% CI 6 fewer to 2 more)

376 (**Table 2** and **Figure 2** and **3**). No evidence of heterogeneity between the studies was

observed in the RR analysis ($I^2=0\%$), although heterogeneity was moderate for the estimation

of RD ($I^2=47.8\%$). The certainty of evidence was graded as type 3 (low) for this outcome,

due to imprecision and inclusion of non-randomized studies (Table 2). In the sensitivity

analysis using the second-order approach, mRNA-1273 vaccination was associated with

numerically reduced risk of death due to COVID-19 compared with BNT162b2 vaccination,

but this was not statistically significant (RR 0.77 [95% CI 0.59–1.01]; Figure 4A and

383 Supplemental Figure S2D).

In subgroup analysis of four studies reporting this outcome in older adults aged ≥ 65 years,

vaccination with mRNA-1273 was associated with fewer COVID-19 deaths versus

386 vaccination with BNT162b2 (RR 0.72 [95% CI 0.54–0.98]; RD 11 fewer deaths per 100,000

individuals vaccinated [95% CI 19 fewer to 4 fewer) (Table 3, Figure 4B, and

388 Supplemental Figure S3E). The evidence suggested that the heterogeneity across studies

might not be important (RR $I^2=10.9\%$). The evidence certainty was graded as type 4 (very

low) in this analysis due to imprecision and limited evidence (**Table 3**). There was no

391 statistically significant difference between the mRNA vaccines against the outcome of COVID-19–related deaths in the subgroup of individuals aged \geq 50 years who received 392 exclusively three vaccine doses, based on analysis of two studies (RR 1.01 [95% CI 0.64-393 394 1.57]; Table 3, Figure 4C, and Supplemental Figure S4E). The mRNA-1273 vaccine was associated with reduced risk of COVID-19-related death compared with BNT162b2 when 395 396 individuals with CEV1/2 group conditions were excluded (Supplementary Figure S6E). There was no statistically significant difference in mortality risk between mRNA vaccines in 397 subgroup analyses of individuals aged \geq 75 years, individuals aged \geq 50 years exposed to 398 399 Delta variant, or in the subgroup excluding those studies with only VE data (Supplemental

401

400

Figures S5E, S7E, and S8D).

402 **DISCUSSION**

This meta-analysis of 24 studies in older adults aged \geq 50 years found that vaccination with mRNA-1273 was statistically significantly associated with lower risk of SARS-CoV-2 infections, including asymptomatic, symptomatic, and severe infections, as well as hospitalizations and deaths due to COVID-19 compared with vaccination with BNT162b2. To our knowledge, this is the first such analysis of pairwise real-world evidence in adults aged 50 years or older. This evidence helps inform considerations about which vaccine to choose for older adults.

410 Older age has consistently been identified as a primary risk factor for worse outcomes with

411 COVID-19 (6, 7, 8), with older adults accounting for the majority of COVID-19–related

412 deaths (2, 3, 5, 62). This meta-analysis provides evidence for improved outcomes with the

413 mRNA-1273 vaccine compared with the BNT162b2 vaccine in older adults. Similarly, high-

414 dose and adjuvanted influenza vaccines have demonstrated improved outcomes over standard

415 dose influenza vaccines in older adults (21, 22), and, as a result, these vaccines are

416 preferentially recommended for the elderly population in many countries (63, 64).

417 Immunology studies have also reported higher antibody production with the mRNA-1273

418 vaccine compared with the BNT162b2 vaccine (19).

Findings from the sensitivity analysis using the second order meta-analysis approach were consistent with the overall results among older adults aged \geq 50 years, except that there was no significant difference between mRNA vaccines for the outcome of COVID-19–related deaths. Consistent findings were also observed in subgroup analyses among adults aged \geq 65 years or \geq 75 years, in adults aged \geq 50 years who received exclusively three doses, in those who did not have CEV groups 1 and 2 conditions, and those infected by the Delta variant, and in the subgroup excluding studies that only reported VE. Across these subgroups, 426 vaccination with mRNA-1273 was associated with significantly fewer infections,

427 symptomatic infections, and severe infections compared with vaccination with BNT162b2. 428 Vaccination with mRNA-1273 was also associated with significantly fewer hospitalizations compared with vaccination with BNT162b2 in each subgroup. Similar results were observed 429 430 for COVID-19-related death, except that there was no significant difference observed for this 431 outcome between the vaccines in the subgroup of adults aged \geq 75 years and in those infected 432 with the Delta variant. Overall, the findings from the base-case analysis were confirmed by a broad range of sensitivity analyses considering different subgroups as well as different 433 434 methodologies (i.e., second order approach and exclusion of VE studies), suggesting that the findings of the meta-analysis are robust. 435

436 Limitations of this systematic review and meta-analysis should be considered. Because all the studies included in the analysis were observational in nature, the certainty of evidence was 437 graded as low or very low (type 3 or below). Furthermore, four of the 24 studies included in 438 439 the meta-analysis had a serious risk of bias, and risk of bias was not estimable for one 440 additional study due to lack of sufficient information. Importantly, the tight timelines for developing variant-adapted vaccines for COVID-19 limits the feasibility of large RCTs. In 441 442 this context, estimates of the comparative effectiveness of COVID-19 vaccines based on realworld evidence provides crucial information to address important clinical questions and 443 inform policy decisions regarding vaccination (65). Nevertheless, higher quality real-world 444 445 evidence studies on vaccine effectiveness are needed, particularly for the outcomes of 446 COVID-19-related hospitalizations and deaths. Possible publication bias was noted based on 447 Egger's regression test (P < 0.05) for the outcomes of symptomatic infections and severe infections. However, the number of studies reporting symptomatic infections was small 448 449 (n=5), limiting the power of Egger's regression test to accurately distinguish chance from 450 true asymmetry. A combination of various endpoints, including severe infection (as defined

by the study), hospitalization, and death, was used to define a composite severe infections 451 outcome in this meta-analysis, introducing additional heterogeneity. This may have 452 453 contributed to the significant asymmetry observed for this outcome. Publication bias was not detected based on Egger's test for outcomes with sufficient numbers of studies in the 454 evidence base (ie, for SARS-2-CoV-2 infections, hospitalizations, and deaths). The studies 455 456 included in our meta-analysis showed a large amount of heterogeneity. This finding is 457 possibly a reflection of the complex interactions between vaccination and contextual factors as they operate in the real world. However, such heterogeneity does introduce challenges in 458 459 predicting true vaccine effectiveness under a given regimen, or for a given population. Various factors could have driven the observed heterogeneity, including differences in study 460 populations, statistical approaches employed, definitions of outcomes (e.g., for severe 461 462 COVID-19), analyzed time points after vaccination, and vaccination schedules and regimens. Such high heterogeneity may also be expected in older populations, in part due to the large 463 heterogeneity in health status associated with underlying comorbidities, for example. Meta-464 regression accounting for some of the factors plausibly driving heterogeneity (such as varying 465 time points of analysis after vaccination and vaccination schedules and regimes) could not be 466 conducted due to sparse data. However, we performed multiple subgroup analyses to account 467 for age differences (i.e., restricted to individuals aged ≥ 65 years and ≥ 75 years), differences 468 in number of vaccine doses (i.e., restricted to individuals who received three doses), 469 470 underlying medical conditions (i.e., excluding those with CEV group 1 and 2 conditions), and 471 SARS-CoV-2 variant (i.e., restricted to a single variant of concern [Delta]) to better understand the source of heterogeneity. Heterogeneity continued to be observed across these 472 473 sub-analyses. Notably, high heterogeneity has also been noted in meta-analyses of influenza vaccine effectiveness in older adults (21, 64, 66). Future studies and reviews examining 474 which factors predict when, where, and for whom the vaccines show differential effectiveness 475

would be beneficial to address possible disparities in protection. Despite the high
heterogeneity we observed, comprehensive sensitivity analyses considering only subsets of
studies (i.e., excluding studies or groups of studies) were conducted, results of which
highlight the robustness of effect sizes and the conclusion of the overall meta-analysis (67).

480 Our evidence synthesis has several considerable strengths. First, we used broad search terms 481 and high-quality systematic literature review methodology, which included training reviewers and validating the included studies and extracted data. Second, we used advanced meta-482 analytical methods to include both studies reporting event and participant numbers by vaccine 483 484 arm as well as studies reporting only VE. This approach allowed for inclusion of all available data, taking into account both within-study and between-study variability, resulting in more 485 486 robust and reliable conclusions than would be possible if either only binary data or only VE data were included. We also carried out a sensitivity analysis using a second-order meta-487 analytical model which demonstrated similar results to the main analysis, corroborating the 488 489 robustness of the data and the analytical methods employed. Finally, this evidence synthesis 490 and meta-analysis provides important updates compared with previous analyses, notably providing results on the comparative effectiveness of the two available mRNA vaccines in 491 492 preventing SARS-CoV-2 infections and associated severe outcomes.

493 Conclusions

494 Vaccination with mRNA-1273 was associated with significantly fewer asymptomatic,

495 symptomatic, and severe infections; hospitalizations; and deaths due to COVID-19 than 496 vaccination with BNT162b2 in older adults aged \geq 50 years, and these differences generally 497 persisted among subgroups of patients, including among older adults aged \geq 65 years and 498 adults aged \geq 50 years who received three doses of the same vaccine. These results can inform

- 499 policy makers who wish to optimize vaccination programs at the population level, as well as
- 500 health care professionals making individual-based recommendations to their patients.

502 DATA SHARING STATEMENT

The original contributions presented in the study are included in the article/Supplementary
Material. Further inquiries can be directed to the corresponding author.

505 AUTHOR CONTRIBUTIONS

EB, KH, XW, and NG designed and performed the systematic literature review and metaanalysis and critically evaluated the manuscript. SK, MN, NKM, MM, and PS performed the
systematic literature review and meta-analysis and critically evaluated the manuscript. EB,
MTB-J, and NV conceptualized the article and provided oversight and critical evaluation of
the manuscript. All authors contributed to the article and approved the submitted version.

511 CONFLICTS OF INTEREST

MTB-J, NV, and EB are employees of Moderna, Inc., and hold stock/stock options in the 512 company. KH, XW, MN, NKM, MM, and PS are employees of ICON plc, a clinical research 513 514 organization paid by Moderna, Inc., to conduct the study. SK is a former employee of ICON plc. NG is an independent consultant employed at University College of London, and was 515 paid by Moderna, Inc., to conduct aspects of this study. This study was funded by Moderna, 516 Inc. Authors employed by Moderna, Inc., were involved in the study design, analysis and 517 518 interpretation of data, the writing of the manuscript, and the decision to submit the manuscript for publication. 519

520 ACKNOWLEDGMENTS

521 Writing assistance was provided by Erin Bekes, PhD, and Sheri Arndt, PharmD, of ICON

- 522 (Blue Bell, PA, USA) in accordance with Good Publication Practice (GPP3) guidelines,
- 523 funded by Moderna, Inc., and under the direction of the authors.

525 **REFERENCES**

- 526 1. World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard 2023
- 527 [updated Oct 18, 2023. Available from: <u>https://covid19.who.int/</u>.
- 528 2. Ahmad FB, Cisewski JA, Xu J, Anderson RN. COVID-19 Mortality Update United
- 529 States, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(18):493-6.
- 530 3. World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard:
- 531 Confirmed and probable COVID-19 cases and deaths by age 2023 [updated October 16,
- 532 2023. Available from:
- 533 <u>https://app.powerbi.com/view?r=eyJrIjoiYWRiZWVkNWUtNmM0Ni00MDAwLTIjYWMt</u>
- 534 <u>N2EwNTM3YjQzYmRmIiwidCI6ImY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4</u>
- 535 <u>MGFmYjU5MCIsImMiOjh9</u>.
- 4. Wong MK, Brooks DJ, Ikejezie J, Gacic-Dobo M, Dumolard L, Nedelec Y, et al.
- 537 COVID-19 Mortality and Progress Toward Vaccinating Older Adults World Health
- 538 Organization, Worldwide, 2020-2022. MMWR Morb Mortal Wkly Rep. 2023;72(5):113-8.
- 539 5. Tejada-Vera B, Kramarow EA. COVID-19 Mortality in Adults Aged 65 and Over: United
- 540 States, 2020. NCHS Data Brief. 2022(446):1-8.
- 6. Hu L, Chen S, Fu Y, Gao Z, Long H, Ren HW, et al. Risk Factors Associated With
- 542 Clinical Outcomes in 323 Coronavirus Disease 2019 (COVID-19) Hospitalized Patients in
- 543 Wuhan, China. Clin Infect Dis. 2020;71(16):2089-98.
- 544 7. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors
- associated with hospital admission and critical illness among 5279 people with coronavirus
- disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.
- 547 8. Sung J, Choudry N, Bachour R. Development and validation of a simple risk score for
- 548 diagnosing COVID-19 in the emergency room. Epidemiol Infect. 2020;148:e273.

- 549 9. Jacob J, Tesch F, Wende D, Batram M, Loser F, Weidinger O, et al. Development of a
- risk score to identify patients at high risk for a severe course of COVID-19. Z Gesundh Wiss.2023:1-10.
- 10. World Health Organization (WHO). WHO SAGE roadmap on uses of COVID-19
- vaccines in the context of OMICRON and substantial population immunity 2023 [updated
- March 30, 2023. Available from: <u>https://www.who.int/publications/i/item/WHO-2019-nCoV-</u>
 Vaccines-SAGE-Roadmap.
- 556 11. Li Z, Liu S, Li F, Li Y, Li Y, Peng P, et al. Efficacy, immunogenicity and safety of
- 557 COVID-19 vaccines in older adults: a systematic review and meta-analysis. Front Immunol.
- 558 2022;13:965971.
- 12. SPIKEVAX. mRNA-1273. Cambridge, MA: ModernaTX, Inc.; 2022.
- 560 13. COMIRNATY. BNT162b2. New York, NY: Pfizer/BioNTech; 2022.
- 14. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety
- of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-16.
- 563 15. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and
- Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15.
- 565 16. Moderna I. Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination
- 566 Providers) Emergency Use Authorization (EUA) of the Moderna COVID-19 Vaccine to
- 567 Prevent Coronavirus Disease 2019 (COVID-19): Primary Series for 12 Years and Older
- 568 Cambridge, MA, USA: Moderna, Inc.; 2022 [updated December 8, 2022. Available from:
- 569 https://eua.modernatx.com/covid19vaccine-eua/eua-fact-sheet-providers.pdf.
- 570 17. Pfizer/BioNTech. Fact Sheet for Healthcare Providers Administering Vaccine
- 571 (Vaccination Providers) Emergency Use Authorization (EUA): Pfizer-BioNTech COVID-19
- 572 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) and Booster Dose for 12 Years of Age

- and Older New York, NY, USA: Pfizer/BioNTech; 2022 [updated December 8, 2022.
- 574 Available from: <u>https://labeling.pfizer.com/ShowLabeling.aspx?id=17675&format=pdf</u>.
- 18. Tahtinen S, Tong AJ, Himmels P, Oh J, Paler-Martinez A, Kim L, et al. IL-1 and IL-1ra
- are key regulators of the inflammatory response to RNA vaccines. Nat Immunol.
- 577 2022;23(4):532-42.
- 578 19. Zhang L, More KR, Ojha A, Jackson CB, Quinlan BD, Li H, et al. Effect of mRNA-LNP
- 579 components of two globally-marketed COVID-19 vaccines on efficacy and stability. NPJ
- 580 Vaccines. 2023;8(1):156.
- 581 20. Cari L, Naghavi Alhosseini M, Mencacci A, Migliorati G, Nocentini G. Differences in the
- 582 Expression Levels of SARS-CoV-2 Spike Protein in Cells Treated with mRNA-Based
- 583 COVID-19 Vaccines: A Study on Vaccines from the Real World. Vaccines (Basel).
- 584 2023;11(4).
- 585 21. Coleman BL, Sanderson R, Haag MDM, McGovern I. Effectiveness of the MF59-
- adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age
- 587 or older, a systematic review and meta-analysis. Influenza Other Respir Viruses.
- 588 2021;15(6):813-23.
- 589 22. Lee JKH, Lam GKL, Shin T, Samson SI, Greenberg DP, Chit A. Efficacy and
- 590 effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic
- 591 match: An updated systematic review and meta-analysis. Vaccine. 2021;39 Suppl 1:A24-
- 592 A35.
- 593 23. Wang X, Haeussler K, Spellman A, Phillips LE, Ramiller A, Bausch-Jurken MT, et al.
- 594 Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in
- immunocompromised individuals: a systematic review and meta-analysis using the GRADE
- 596 framework. Front Immunol. 2023;14:1204831.

- 597 24. Schünemann HB, Jan; Guyatt, Gordon; Oxman, Andrew, editor. Handbook for grading
- the quality of evidence and the strength of recommendations using the GRADE approach:
- 599 The GRADE Working Group; 2013.
- 600 25. Ahmed F, Temte JL, Campos-Outcalt D, Schünemann HJ. Methods for developing
- 601 evidence-based recommendations by the Advisory Committee on Immunization Practices
- 602 (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC). Vaccine.
- 603 2011;29(49):9171-6.
- 604 26. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
- 605 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ.
- 606 2021;372:n71.
- 607 27. WHO COVID-19 Research Database: user guide and information: World Health
- 608 Organization; 2023 [updated September 1, 2023. Available from:
- 609 https://www.who.int/publications/m/item/quick-search-guide-who-covid-19-database#News.
- 610 28. BC COVID Therapeutics Committee. Practice Tool #2 Definitions of
- 611 CEV/Immunosuppressed British Columbia, Canada: BC Centre for Disease Control; 2022
- 612 [updated July 25, 2022. Available from: <u>http://www.bccdc.ca/Health-Professionals-</u>
- 613 <u>Site/Documents/COVID-treatment/PracticeTool2_CEVCriteria.pdf</u>.
- 614 29. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-
- 615 Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses
- 616 [Available from: <u>https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</u>.
- 617 30. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials.
- 618 1986;7(3):177-88.
- 619 31. VanderWeele TJ. Optimal approximate conversions of odds ratios and hazard ratios to
- 620 risk ratios. Biometrics. 2020;76(3):746-52.

- 621 32. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect
- treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol.
 1997;50(6):683-91.
- 624 33. Daly C, Anwer S, Welton NJ, Dias S, Ades A. Meta-Analysis of Event Outcomes:
- 625 Guideline Methodology Document 3: NICE Guidelines Technical Support Unit; 2021
- 626 [Available from: <u>https://www.bristol.ac.uk/population-health-</u>
- 627 <u>sciences/centres/cresyda/mpes/nice/guideline-methodology-documents-gmds/</u>.
- 628 34. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice
- 629 of axis. J Clin Epidemiol. 2001;54(10):1046-55.
- 630 35. Sterne JAC, Egger M. Regression Methods to Detect Publication and Other Bias in Meta-
- Analysis. In: Rothstein HR, Sutton AJ, Borenstein M, editors.2005.
- 632 36. Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane
- Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023):
- 634 Cochrane. Available from <u>www.training.cochrane.org/handbook;</u> 2023.
- 635 37. Schwarzer G. meta: An R package for meta-analysis. R News. 2007;7(3):40-5.
- 636 38. Viechtbauer W. Conducting meta-analyses in R with the metafor package. Journal of
- 637 Statistical Software. 2010;36(3):1-48.
- 638 39. Anderegg N, Althaus CL, Colin S, Hauser A, Laube A, Mausezahl M, et al. Assessing
- 639 real-world vaccine effectiveness against severe forms of SARS-CoV-2 infection: an
- observational study from routine surveillance data in Switzerland. Swiss Med Wkly.
- 641 2022;152:w30163.
- 40. Breznik JA, Rahim A, Kajaks T, Hagerman M, Bilaver L, Colwill K, et al. Protection
- 643 from Omicron Infection in Residents of Nursing and Retirement Homes in Ontario, Canada. J
- 644 Am Med Dir Assoc. 2023;24(5):753-8.

- 645 41. Grewal R, Kitchen SA, Nguyen L, Buchan SA, Wilson SE, Costa AP, et al. Effectiveness
- of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term
- care residents in Ontario, Canada: test negative design study. BMJ. 2022;378:e071502.
- 42. Butt AA, Talisa VB, Yan P, Shaikh OS, Omer SB, Mayr FB. Vaccine Effectiveness of 3
- 649 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- mRNA Vaccines in a High-Risk National Population. Clin Infect Dis. 2022;75(1):e579-e84.
- 43. Hatfield KM, Baggs J, Wolford H, Fang M, Sattar AA, Montgomery KS, et al.
- 652 Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccination Against Severe Acute
- 653 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Residents of US
- Nursing Homes Before and During the Delta Variant Predominance, December 2020-
- 655 November 2021. Clin Infect Dis. 2022;75(Suppl 2):S147-S54.
- 44. Kelly JD, Leonard S, Hoggatt KJ, Boscardin WJ, Lum EN, Moss-Vazquez TA, et al.
- 657 Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2,
- 658 mRNA-1273, and Ad26.COV2.S Vaccines. Jama. 2022;328(14):1427-37.
- 45. Moline HL, Whitaker M, Deng L, Rhodes JC, Milucky J, Pham H, et al. Effectiveness of
- 660 COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged >/=65 Years -
- 661 COVID-NET, 13 States, February-April 2021. MMWR Morb Mortal Wkly Rep.
- 662 2021;70(32):1088-93.
- 46. Puranik A, Lenehan PJ, Silvert E, Niesen MJM, Corchado-Garcia J, O'Horo JC, et al.
- 664 Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-
- 665 2 infection. Med. 2022;3(1):28-41 e8.
- 47. Robles-Fontan MM, Nieves EG, Cardona-Gerena I, Irizarry RA. Effectiveness estimates
- of three COVID-19 vaccines based on observational data from Puerto Rico. Lancet Reg
- 668 Health Am. 2022;9:100212.

- 48. Rosenberg ES, Dorabawila V, Easton D, Bauer UE, Kumar J, Hoen R, et al. Covid-19
- 670 Vaccine Effectiveness in New York State. N Engl J Med. 2022;386(2):116-27.
- 49. Thompson MG, Stenehjem E, Grannis S, Ball SW, Naleway AL, Ong TC, et al.
- 672 Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. N Engl J
- 673 Med. 2021;385(15):1355-71.
- 50. Weng CH, Zhou S, Saal A, Hafferty M, McGuire DC, Chan PA. BNT162b2 and mRNA-
- 675 1273 Vaccine Effectiveness against SARS-CoV-2 and Variants in the Urban Underserved
- 676 Population. R I Med J (2013). 2023;106(1):26-8.
- 51. Lin DY, Gu Y, Wheeler B, Young H, Holloway S, Sunny SK, et al. Effectiveness of
- 678 Covid-19 Vaccines over a 9-Month Period in North Carolina. N Engl J Med.
- 679 2022;386(10):933-41.
- 52. Hung Nguyen V, Boileau C, Bogdanov A, Sredl M, Bonafede M, Ducruet T, et al.
- 681 Relative Effectiveness of BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines and
- 682 Homologous Boosting in Preventing COVID-19 in Adults in the US. Open Forum Infectious
- 683 Diseases. 2023;10(7):ofad288.
- 53. Braeye T, Catteau L, Brondeel R, van Loenhout JAF, Proesmans K, Cornelissen L, et al.
- 685 Vaccine effectiveness against transmission of alpha, delta and omicron SARS-COV-2-
- 686 infection, Belgian contact tracing, 2021-2022. Vaccine. 2023;41(20):3292-300.
- 687 54. Lytras T, Kontopidou F, Lambrou A, Tsiodras S. Comparative effectiveness and
- durability of COVID-19 vaccination against death and severe disease in an ongoing
- nationwide mass vaccination campaign. J Med Virol. 2022;94(10):5044-50.
- 690 55. Voko Z, Kiss Z, Surjan G, Surjan O, Barcza Z, Palyi B, et al. Nationwide effectiveness of
- 691 five SARS-CoV-2 vaccines in Hungary-the HUN-VE study. Clin Microbiol Infect.
- 692 2022;28(3):398-404.

- 693 56. Voko Z, Kiss Z, Surjan G, Surjan O, Barcza Z, Wittmann I, et al. Effectiveness and
- 694 Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the
- 695 Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study). Front Immunol.
- *696* 2022;13:919408.
- 697 57. Starrfelt J, Danielsen AS, Buanes EA, Juvet LK, Lyngstad TM, Ro GOI, et al. Age and
- 698 product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation
- among adults in Norway: a national cohort study, July-November 2021. BMC Med.

700 2022;20(1):278.

- 58. van Ewijk CE, Kooijman MN, Fanoy E, Raven SF, Middeldorp M, Shah A, et al.
- 702 COVID-19 vaccine effectiveness against SARS-CoV-2 infection during the Delta period, a
- nationwide study adjusting for chance of exposure, the Netherlands, July to December 2021.
- 704 Euro Surveill. 2022;27(45).
- 59. Chico-Sanchez P, Gras-Valenti P, Algado-Selles N, Jimenez-Sepulveda N, Vanaclocha H,
- Peiro S, et al. The effectiveness of mRNA vaccines to prevent SARS-CoV-2 infection and
- 707 hospitalisation for COVID-19 according to the time elapsed since their administration in
- health professionals in the Valencian Autonomous Community (Spain). Prev Med.

709 2022;163:107237.

- 710 60. Martinez-Baz I, Trobajo-Sanmartin C, Miqueleiz A, Guevara M, Fernandez-Huerta M,
- 711 Burgui C, et al. Product-specific COVID-19 vaccine effectiveness against secondary
- infection in close contacts, Navarre, Spain, April to August 2021. Euro Surveill. 2021;26(39).
- 713 61. Kissling E, Hooiveld M, Martinez-Baz I, Mazagatos C, William N, Vilcu AM, et al.
- 714 Effectiveness of complete primary vaccination against COVID-19 at primary care and
- 715 community level during predominant Delta circulation in Europe: multicentre analysis, I-
- 716 MOVE-COVID-19 and ECDC networks, July to August 2021. Euro Surveill. 2022;27(21).

- 717 62. Kim L, Garg S, O'Halloran A, Whitaker M, Pham H, Anderson EJ, et al. Risk Factors for
- 718 Intensive Care Unit Admission and In-hospital Mortality Among Hospitalized Adults
- 719 Identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization
- Surveillance Network (COVID-NET). Clin Infect Dis. 2021;72(9):e206-e14.
- 63. Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK, et al.
- 722 Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the
- Advisory Committee on Immunization Practices United States, 2022-23 Influenza Season.
- 724 MMWR Recomm Rep. 2022;71(1):1-28.
- 64. Domnich A, de Waure C. Comparative effectiveness of adjuvanted versus high-dose
- seasonal influenza vaccines for older adults: a systematic review and meta-analysis. Int J
- 727 Infect Dis. 2022;122:855-63.
- 65. Bhatt A. Real-world data in COVID-19 pandemic: An essential unmet health-care need.
- 729 Perspect Clin Res. 2020;11(3):103-5.
- 730 66. Robert Koch Institut. STIKO: Aktualisierung der Influenza-Impfempfehlung für Personen
- im Alter von ≥ 60 Jahren. Epidemiologisches Bulletin. 2021(January).
- 732 67. Higgins JP. Commentary: Heterogeneity in meta-analysis should be expected and
- appropriately quantified. Int J Epidemiol. 2008;37(5):1158-60.
- 68. Bello-Chavolla OY, Antonio-Villa NE, Valdes-Ferrer SI, Fermin-Martinez CA,
- 735 Fernandez-Chirino L, Vargas-Vazquez A, et al. Effectiveness of a nationwide COVID-19
- vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death:
- a retrospective analysis of national surveillance data. Int J Infect Dis. 2023;129:188-96.
- 69. Chemaitelly H, Ayoub HH, AlMukdad S, Coyle P, Tang P, Yassine HM, et al. Protection
- 739 from previous natural infection compared with mRNA vaccination against SARS-CoV-2
- infection and severe COVID-19 in Qatar: a retrospective cohort study. Lancet Microbe.
- 741 2022;3(12):e944-e55.

- 742 70. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-
- analyses of controlled trials with binary endpoints. Stat Med. 2006;25(20):3443-57.
- 744 71. Oh I-S. Beyond Meta-Analysis: Secondary Uses of Meta-Analytic Data. Annual Review
- of Organizational Psychology and Organizational Behavior. 2020;7:125-53.
- 746 72. Grana C, Ghosn L, Evrenoglou T, Jarde A, Minozzi S, Bergman H, et al. Efficacy and
- safety of COVID-19 vaccines. Cochrane Database Syst Rev. 2022;12(12):CD015477.
- 748 73. Sadeghi S, Kalantari Y, Shokri S, Fallahpour M, Nafissi N, Goodarzi A, et al.
- 749 Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in
- 750 Healthy and immunosuppressed Children and Adolescents Aged 2 21 years old: A
- 751 Systematic Review and Meta-analysis. J Clin Virol. 2022;153:105196.
- 752 74. Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al.
- 753 Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease:
- results of a systematic review and meta-regression. Lancet. 2022;399(10328):924-44.
- 755 75. Asghar N, Mumtaz H, Syed AA, Eqbal F, Maharjan R, Bamboria A, et al. Safety,
- efficacy, and immunogenicity of COVID-19 vaccines; a systematic review. Immunol Med.
- 757 2022;45(4):225-37.
- 758 76. Rahmani K, Shavaleh R, Forouhi M, Disfani HF, Kamandi M, Oskooi RK, et al. The
- r59 effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality
- from COVID-19: A systematic review and meta-analysis. Front Public Health.
- 761 2022;10:873596.
- 762 77. Korang SK, von Rohden E, Veroniki AA, Ong G, Ngalamika O, Siddiqui F, et al.
- 763 Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis
- and network meta-analysis of randomized clinical trials. PLoS One. 2022;17(1):e0260733.

- 765 78. Mohammed I, Nauman A, Paul P, Ganesan S, Chen KH, Jalil SMS, et al. The efficacy
- and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization,
- and mortality: a systematic review. Hum Vaccin Immunother. 2022;18(1):2027160.
- 768 79. Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of
- 769 COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis. 2022;114:252-60.
- 80. Au WY, Cheung PP. Effectiveness of heterologous and homologous covid-19 vaccine
- regimens: living systematic review with network meta-analysis. BMJ. 2022;377:e069989.
- 81. Lv J, Wu H, Xu J, Liu J. Immunogenicity and safety of heterologous versus homologous
- prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a
- systematic review. Infect Dis Poverty. 2022;11(1):53.
- 82. Iheanacho CO, Eze UIH, Adida EA. A systematic review of effectiveness of BNT162b2
- mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population. Bull
- 777 Natl Res Cent. 2021;45(1):150.
- 83. Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, Immunogenicity and Safety of
- 779 COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Front Immunol.
- 780 2021;12:714170.
- 781 84. Rotshild V, Hirsh-Raccah B, Miskin I, Muszkat M, Matok I. Comparing the clinical
- efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Sci Rep.
 2021;11(1):22777.
- 85. Chen M, Yuan Y, Zhou Y, Deng Z, Zhao J, Feng F, et al. Safety of SARS-CoV-2
- vaccines: a systematic review and meta-analysis of randomized controlled trials. Infect Dis
- 786 Poverty. 2021;10(1):94.
- 787 86. Kow CS, Hasan SS. Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-
- analysis of large observational studies. Inflammopharmacology. 2021;29(4):1075-90.

TABLES

Table 1. Characteristics of studies included in the meta-analysis

	Study characteristics										Ou	tcomes repo	rted	
Author, year	Design	Country and data source	Age group(s)	CEV group 1/2	CEV group 3	SARS CoV-2 testing method	No. Vaccine doses	Study period	Vaccinated, n	Infection	Sympto- matic infection	Severe infection ^a	Hospital- ization	Death
Bello-Chavolla 2023 (68)	Retrospective analysis	Mexico SISVER database	• ≥60 y	ND	Y	RT-PCR and/or antigen test	2 doses (MM vs PP)	Dec 2020– Sep 2021	BNT162b2: 47,694 mRNA-1273: 1,155	Y	N	Y	N	Y
Braeye 2023 (53)	Retrospective cohort study	 Belgium Belgium data collected between Jan 2021 and Jan 2022 	• 65–85 y	ND	ND	RT-PCR test	2 doses (MM vs PP)	Jan 2021– Jan 2022	 BNT162b2: 13,613 mRNA-1273: 1,155 	Y	N	N	N	N
Breznik 2023 (40)	Retrospective cohort study	 Canada 17 nursing homes and 8 retirement homes in Ontario, Canada 	• ≥50 y	ND	ND	Nasopharyn geal PCR and/or circulating antinucleo- capsid IgG antibodies	3 doses (MMM vs PPP)	Dec 2021– May 2022	 BNT162b2: 478 mRNA-1273: 420 	Y	N	N	N	N
Butt 2022 (42)	Retrospective cohort study	USA VA Healthcare System COVID-19 Shared Data Resource	• ≥50 y	Y	Y	PCR test	3 doses (MMM vs PPP)	Apr 2021– Sep 2021	 BNT162b2: 236,693 mRNA-1273: 158,993 	Y	Y	Y	Y	Y
Chemaitelly 2022 (69)	Retrospective cohort study	 Qatar The national, federated databases of the Qatar 	• ≥50 y	ND	Y	PCR and/or antigen test	2 doses (MM vs PP)	Feb 2020– May 2022	 BNT162b2: 180,790 mRNA-1273: 79,456 	Y	N	N	N	N

							Ou	tcomes repo	rted					
Author, year	Design	Country and data source	Age group(s)	CEV group 1/2	CEV group 3	SARS CoV-2 testing	No. Vaccine doses	Study period	Vaccinated, n	Infection	Sympto- matic infection	Severe infection ^a	Hospital- ization	Death
						method	40000							
		Ministry of Public Health												
Chico-Sanchez 2022 (59)	Test-negative case control	 Spain Health Information Systems Analysis Service of the Ministry of Universal Health and Public Health 	• ≥60 y	Y	Y	PCR and/or antigen test	2 doses (MM vs PP)	Jan 2021– Jul 2021	BNT162b2: 264mRNA-1273: 32	Y	N	N	Ν	Ν
Grewal 2022 (41)	• Test-negative case control	Canada Provincial databases	• ≥60 y	Y	Y	RT-PCR test	3 doses (MMM vs PPP)	Dec 2021– Apr 2022	 BNT162b2: 48,706^b mRNA-1273: 57,604^b 	Y	Y	Y	N	N
Hatfield 2022 (43)	Retrospective cohort study	 USA Data from 105 nursing homes 	• ≥50 y	Y	Y	RT-PCR and/or antigen test, or diagnostic code	2 doses (MM vs PP)	Dec 2020– Nov 2021	Pre-Delta period: • BNT162b2: 1196 • mRNA-1273: 466 Delta period: • BNT162b2: 687 • mRNA-1273: 409	Y	N	N	N	N
Kelly 2022 (44)	Retrospective cohort study	 USA Department of VA Corporate Data Warehouse and COVID19 Shared Data Resource 	• ≥65 y	N	N	Laboratory confirmed test, method not specified	3 doses (MMM vs PPP)	Jul 2021– May 2022	 BNT162b2: 83,998 mRNA-1273: 100,751 	Y	Y	Y	N	Ν
Kissling 2022 (61)	Test negative design	 Europe Medical records care/community study 	• ≥60 y	Y	Y	PCR or antigen test	2 doses (MM vs PP)	Jul 2021– Aug 2021	BNT162b2: 2949mRNA-1273: 263	Y	Y	N	N	N

				Study ch	aracteristi	cs					Ou	tcomes repo	rted	
Author, year	Design	Country and data source	Age group(s)	CEV group 1/2	CEV group 3	SARS CoV-2 testing	No. Vaccine doses	Study period	Vaccinated, n	Infection	Sympto- matic infection	Severe infection ^a	Hospital- ization	Death
				1/2	5	method	uoses				meetion			
		sites, questionnaire and vaccine registry linkage												
Lin 2022	• Retrospective	• USA	Overall:	ND	ND	Laboratory	2 doses	Dec	≥50 y:	Y	N	Y	Y	Y
(51)	cohort study	NC COVID	• ≥50 y			confirmed	(MM vs	2020-	• BNT162b2: 1,474,746					
			Subgroup:			test,	PP)	Sep 2021	• mRNA-1273: 1,379,569					
			• ≥65 y			method not			≥65 y:					
						specified			• BNT162b2: 694,655					
									• mRNA-1273: 734,228					
Lytras 2022	• Retrospective	• Greece	• 60–79 y	ND	ND	PCR or	2 doses	Jan 2021-	• ND	N	N	Y	N	Y
(54)	cohort study	• Active surveillance and				antigen test	(MM vs	Dec 2021						
		vaccination registry					PP)							
Martinez-Baz	Prospective	• Spain	● ≥60 y	ND	ND	RT-PCR	2 doses	Apr	• BNT162b2: 2109	Y	N	Ν	N	Ν
2021	dynamic cohort	Regional vaccination				and/or	(MM vs	2021-	• mRNA-1273: 215					
(60)	study	register				antigen test	PP)	Aug 2021						
Moline 2021	Retrospective	• USA	Overall:	ND	ND	Laboratory	2 doses	Feb 2021-	≥65 y:	N	N	Y	Y	Ν
(45)	cohort study	COVID-NET	• ≥65 y			confirmed	(MM vs	Apr 2021	• BNT162b2: 258					
			Subgroup:			test,	PP)		• mRNA-1273: 112					
			• ≥75 y			method not			≥75 y:					
						specified			• BNT162b2: 185					
									• mRNA-1273: 56					
Nguyen 2023	Retrospective	• USA	Overall:	Y	Y	PCR or	3 doses	Feb 2021-	≥65 y:	Y	N	N	Y	N
(52) ^c	cohort study	Integrated real-world	• ≥65 y			antigen test	(MMM vs	Jan 2022	• BNT162b2: 45,285					
		electronic health record	Subgroup:				PPP)		• mRNA-1273: 45,285					
		data set (Veradigm	• ≥75 y						≥75 y:					
		Health Insights),	-						• BNT162b2: 11,404					
									• mRNA-1273: 11,404					

			cs					Ou	tcomes repoi	ted				
Author, year	Design	Country and data source	Age group(s)	CEV group	CEV group	SARS CoV-2	No. Vaccine	Study period	Vaccinated, n	Infection	Sympto- matic	Severe infection ^a	Hospital- ization	Death
		source	group(s)	1/2	3	testing	doses	periou			infection	miccuon	ization	
				1/2	5	method	uoses				milection			
		pharmacy and medical				momou								
		claims data												
Puranik 2022	Retrospective	• USA	Overall:	ND	ND	PCR test	2 doses	Dec	≥50 y:	Y	Y	Ν	N	Ν
(46)	cohort and test-	Health records (Mayo	• ≥50 y				(MM vs	2020-	• BNT162b2: 7119					
	negative case-	Clinic Health System)	Subgroups:				PP)	Sep 2021	• mRNA-1273: 4105					
	control analysis		• ≥65 y						≥65 y:					
			● ≥75 y						• BNT162b2: 4,478					
									• mRNA-1273: 2,878					
									≥75 y:					
									• BNT162b2: 2,249					
									• mRNA-1273: 1,148					
Robles-Fontan	Retrospective	• USA	Overall:	ND	ND	Laboratory	2 doses	Dec	≥55 y:	N	N	Y	Y	Y
2022	cohort study	National level data	• ≥55 y			confirmed	(MM vs	2020-	• BNT162b2: 453,015					
(47)		from Department of	Subgroups:			test,	PP)	Oct 2021	• mRNA-1273: 402,102					
		Health databases	• ≥65 y			method not			≥65 y:					
		(BioPortal and	• \geq 75 y			specified			• BNT162b2: 260,344					
		Electronic							• mRNA-1273: 262,626					
		Immunization System)							≥75 y:					
									• BNT162b2: 112,715					
									• mRNA-1273: 116,566					
Rosenberg 2022	Surveillance-	• USA	Overall:	ND	ND	PCR and/or	2 doses	May	≥50 y:	Y	N	Y	Y	Ν
(48)	based cohort	• Data from databases	• ≥50 y			antigen test	(MM vs	2021-	• BNT162b2: 1,793,698					
		linked to cohort (CIR,	Subgroup:				PP)	Sep 2021	• mRNA-1273: 1,614,377					
		NYSIIS, ECLRS,	• ≥65 y						≥65 y:					
		HERDS)							• BNT162b2: 968,198					
									• mRNA-1273: 1,006,002					

Author, your Design Country and data source Age group CEV CEV CEV CAV2 Vaccine descention Study Vaccinated, n Infection Symple Revere infection Image Infection Symple Revere infection Infection					Study ch	aracteristi	cs					Ou	tcomes repoi	rted	
InterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterfaceInterface	Author, year	Design	Country and data	Age	CEV	CEV	SARS	No.	Study	Vaccinated, n	Infection	Sympto-	Severe	Hospital-	Death
Sturfelt 2022 (57)• Retrospective cohort study• Norway • Norway • Norway (57)• Norway cohort study • Inked data from Norwegia National Preparedness Register for COVID-19 + six different registries• 265 y PY Y PY P 			source	group(s)	group	group	CoV-2	Vaccine	period			matic	infection ^a	ization	
$ \begin{array}{c} Surfield 2022 \\ (57) \\ (57) \\ (57) \\ (57) \\ (57) \\ (57) \\ (57) \\ (57) \\ (57) \\ (57) \\ (57) \\ (57) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\ (56) \\$					1/2	3	testing	doses				infection			
							method								
Image: Norwegian National Preparedness Register for COVID-19 + six different registriesNorwegian National Preparedness Register for COVID-19 + six different registriesPrepare Preparedness Register for COVID-19 + six different registriesNoNNNNveks 2021 (SS)Test-negative cohort study• Netherlands + Hungary (nationwide (nationwide (nationwide or ohort study)• Sefs y subgroups: eofs y eofs y e	Starrfelt 2022	Retrospective	• Norway	● ≥65 y	Y	Y	PCR test	3 doses	Jul 2021-	• ND	Y	N	Y	Y	N
ProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportionProportion	(57)	cohort study	 Linked data from 					(MMM vs	Nov 2021						
Image: Intermediate intermediation in the seven VISION US activation· ≥50 yYYYRT-PCR test2 doesJan 2021. University· BNT162b2: 8,500YNNNNN(49)· Data from the electronic records from the seven VISION US activation· Data from National Public Health Centre· ≥50 yYYYRT-PCR test2 doeseJan 2021.· BNT162b2: 8,500YNNNNNNvan Ewijk 2022· Test-negative case-control study· Netherlands· ≥50 yYYYL EAT or LPAT or LAMP test· BNT162b2: 2,542YNNNNNN(58)· Retrospective control study· Nat from National Public Health Centre· ≥65 yYYYPCR and/or3 dosesSep 2021-· NIDYNYYYYVokó 2022a· Retrospective cohort study· Hungary· ≥55 yYYYPCR and/or3 dosesSep 2021-· NIDYNYYYY(55)· Cohort study· Data from National Public Health Centre· =55 yNDNDPCR and/or2 dosesJan 2021-≥55 y· NIDYNYNYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY </td <td></td> <td></td> <td>Norwegian National</td> <td></td> <td></td> <td></td> <td></td> <td>PPP)</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>			Norwegian National					PPP)							
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$			Preparedness Register												
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			for COVID-19 + six												
			different registries												
$ \begin{array}{ c c c c c c c c } \hline Study & electronic records from the seven VISION US network \\ \hline van Ewijk 2022 \\ (58) \\ \hline van Ewijk 2022 \\ (58) \\ \hline van Ewijk 2022 \\ (58) \\ \hline van Ewijk 2022 \\ (56) \\ \hline vokó 2022 \\ (56) \\ \hline vokó 2022 \\ (56) \\ \hline vokó 2022 \\ (55) \\ \hline vokó 2022 \\ (ationwide \\ cohort study \\ (nationwide \\ vokó 2022 \\ (55) \\ \hline vokó 2022 \\ \hline vokó 202 \\ \hline vokó$	Thompson 2021	Test-negative	• USA	● ≥50 y	Y	Y	RT-PCR	2 doses	Jan 2021-	• BNT162b2: 8,500	Y	N	N	N	Ν
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	(49)	case-control	• Data from the				test	(MM vs	Jun 2021	• mRNA-1273: 6,374					
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		study	electronic records from					PP)							
van Ewijk 2022 (58)• Test-negative case-control study• Netherlands · Data from Public Health Service testing facilities• ≥ 50 y · Data from Public Health Service testing facilities• Y · Data from Public · Health Service testing facilitiesY · Data from Public · Health Service testing facilitiesV · Data from Public · Health Service testing facilities• ≥ 50 y · Data from National Public Health CentreY · Data from National Public Health CentreV · Dec · Data from National Public Health Centre· ≥ 55 y · ≥ 75 yY · VV · NDPCR and/or antigen testJul 2021- (MM vs PP)· BNT162b2: 2,542 · Dec 2021 · Dec 2021 · mRNA-1273: 273N · NDN · NN · NN · NN · NVokó 2022 (50)• Retrospective cohort study (nationwide cohort study)• Hungary · Data from National Public Health Centre subgroups: · ≥ 55 y · ≥ 75 yV · NDND · PCR and/or antigen test3 doses · MM vs · PP)Sep 2021- · Dec 2021 · Dec 2021 · Dec 2021 · ND• ND · NDY · NDN · NDY · NDY · NDN · NY · NN · NY · N <td></td> <td></td> <td>the seven VISION US</td> <td></td>			the seven VISION US												
			network												
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	van Ewijk 2022	• Test-negative	Netherlands	• ≥50 y	Y	Y	LFAT or	2 doses	Jul 2021-	• BNT162b2: 2,542	Y	N	N	N	Ν
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	(58)	case-control	• Data from Public				RT-PCR or	(MM vs	Dec 2021	• mRNA-1273: 273					
Vokó 2022 (56)• Retrospective cohort study (nationwide cohort study)• Hungary · Data from National Public Health Centre• ≥ 65 y · Data from National Public Health CentreY · NN · NY · NN · NY · NY · NY · NY · NN · NY · NN · NY · NN · NY · NN · NY · NN · NY · NN ·		study	Health Service testing				LAMP test	PP)							
			facilities												
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Vokó 2022	Retrospective	Hungary	• ≥65 y	Y	Y	PCR and/or	3 doses	Sep 2021–	• ND	Y	N	Y	Y	Y
cohort study)cohort studyNDNDPCR and/or2 dosesJan 2021- ≥ 55 yYNYNY(55) \circ cohort study (nationwide cohort study) \circ Data from National Public Health Centre $\circ \geq 75$ y $\circ \geq 55$ y $\circ \geq 55$ y $\circ = 255$ y <td>(56)</td> <td>cohort study</td> <td>• Data from National</td> <td></td> <td></td> <td></td> <td>antigen test</td> <td>(MMM vs</td> <td>Dec 2021</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	(56)	cohort study	• Data from National				antigen test	(MMM vs	Dec 2021						
Vokó 2022a (55)• Retrospective cohort study (nationwide cohort study)• HungaryOverall:NDNDPCR and/or antigen testJan 2021- (MM vs PP) ≥ 55 yYNYNYNY(55)• Data from National (nationwide cohort study)• Data from National Public Health Centre ≥ 65 y ≥ 75 y• ≥ 55 ySubgroups: $\bullet \geq 75$ yNDPCR and/or antigen test2 doses (MM vs PP)Jan 2021- PP) ≥ 55 yYNYNY• Data from National (nationwide cohort study)• Data from National Public Health Centre $\bullet \geq 75$ y• ≥ 55 y $\bullet \geq 75$ yNDPCR and/or antigen testIan 2021- (MM vs PP) ≥ 55 y \bullet • BNT162b2: 845,906 \bullet Ian 2021- \bullet • BNT162b2: 845,906 \bullet Ian 2021- \bullet • BNT162b2: 613,035Ian 2021- \bullet Ian 2021- \bullet • BNT162b2: 613,035Ian 2021- \bullet Ian 2021- \bullet <td></td> <td>(nationwide</td> <td>Public Health Centre</td> <td></td> <td></td> <td></td> <td></td> <td>PPP)</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>		(nationwide	Public Health Centre					PPP)							
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		cohort study)													
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Vokó 2022a	Retrospective	• Hungary	Overall:	ND	ND	PCR and/or	2 doses	Jan 2021-	≥55 y	Y	N	Y	N	Y
cohort study) $\bullet \ge 65 \text{ y}$ $\bullet \ge 75 \text{ y}$ $\bullet \ge 75 \text{ y}$	(55)	cohort study	Data from National	• ≥55 y			antigen test	(MM vs	Jun 2021	• BNT162b2: 845,906					
• ≥75 y • BNT162b2: 613,035		(nationwide	Public Health Centre	Subgroups:				PP)		• mRNA-1273: 116,247					
		cohort study)		• ≥65 y						≥65 y:					
• mRNA-1273: 80,521				● ≥75 y						• BNT162b2: 613,035					
										• mRNA-1273: 80,521					
≥75 y:										≥75 y:					

				Study ch	aracteristi	es					Ou	tcomes repor	ted	
Author, year	Design	Country and data	Age	CEV	CEV	SARS	No.	Study	Vaccinated, n	Infection	Sympto-	Severe	Hospital-	Death
		source	group(s)	group	group	CoV-2	Vaccine	period			matic	infection ^a	ization	
				1/2	3	testing	doses				infection			
						method								
									• BNT162b2: 302,956					
									• mRNA-1273: 41,403					
Weng 2023	Cohort study	• USA	• ≥55 y	ND	ND	RT-PCR	2 doses	Jan 2021-	• ND	Y	Ν	Ν	Ν	Ν
(50)		 Data from a major 				test	(MM vs	Dec 2021						
		FQHC in Rhode Island					PP)							

792 CEV, clinically extremely vulnerable; CIR, Citywide Immunization Registry; COVID-NET, COVID-19–Associated Hospitalization

793 Surveillance Network; ECLRS, Electronic Clinical Laboratory Reporting System; FQHC, federally qualified health center; HERDS, Health

794 Electronic Response Data System; LAMP, loop-mediated isothermal amplification; LFAT, lateral-flow antigen test; N, no; NC COVID, North

795 Carolina COVID-19 Surveillance System; ND, not disclosed; NYSIIS, New York City, and the New York State Immunization Information

796 System; PCR, polymerase chain reaction; RT, reverse transcription; SISVER, Sistema de Vigilancia Epidemiológica de Enfermedades

797 Respiratorias (nationwide sentinel surveillance system); VA, Veterans Affairs; Y, yes.

Vaccine dosing abbreviated as MM or MMM for 2 or 3 doses of mRNA-1273, respectively, and PP or PPP for 2 or 3 doses of BNT162b2,

respectively.

⁸⁰⁰ ^aDerived severe infections (based on either severe infection as defined in the study or hospitalization data or death data).

^bNumber of vaccinated participants included in the infection analysis. For the symptomatic infection analysis, n=2139 (BNT162b2) and n=1831

(mRNA-1273); for the severe infection analysis, n=1,638 (BNT162b2) and n=1,518 (mRNA-1273).

^cIndustry sponsored study (Moderna, Inc).

804 **Table 2. Summary of overall GRADE findings.**

			Certainty	assessment			mRNA-1273,	BNT162b2,	Effect	Effect absolute	
Study, n	Study design	RoB	Inconsistency	Indirectness	Imprecision	Other considerations	n/N (%)	n/N (%)	relative (95% CI)	(95% CI)	Certainty
SARS-CoV-2 i	nfection										
22	NR	Serious ^a	Serious ^b	Serious ^c	Serious ^d	Strong association	11,122/	21,068/	RR 0.72	442 fewer per	Type 4 ^e
							2,185,984	3,273,582	(0.64–0.80)	100,000	
							(0.51%)	(0.64%)		(from 570 fewer to	
										313 fewer)	
Symptomatic S	SARS-CoV-	2 infection	•			•	•				
5	NR	Not serious	Serious ^f	Not serious	Very serious ^g	Strong association,	1,628/	2,980/	RR 0.72	609 fewer per	Type 3 ^h
						possible publication bias	265,943	332,898	(0.62–0.83)	100,000	
							(0.61%)	(0.90%)		(from 980 fewer to	
										238 fewer)	
Severe SARS-	CoV-2 Infe	ction				L					
12	NR	Serious ⁱ	Not serious ^j	Serious ^k	Serious ¹	Strong association,	1,030/	2,025/	RR 0.67	20 fewer per	Type 4 ^m
						possible publication bias	2,393,992	3,414,948	(0.57–0.78)	100,000	
							(0.04%)	(0.06%)		(from 29 fewer to	
										11 fewer)	
Hospitalization	n due to CO	VID-19									
8	NR	Serious ⁿ	Not serious ^o	Not serious ^p	Serious ¹	Strong association	872/	1,581/	RR 0.65	23 fewer per	Type 3 ^h
							2,220,757	2,528,691	(0.53-0.79)	100,000	
							(0.04%)	(0.06%)		(from 34 fewer to	
										12 fewer)	
Death due to C	COVID-19	I				<u> </u>	<u> </u>				
7	NR	Serious ^q	Not serious ^r	Not serious ^p	Serious ^s	Strong association	81.5/	345.5/	RR 0.80	2 fewer per	Type 3 ^h
							677,343	1,535,615	(0.64–0.99)	100,000	
							(0.01%)	(0.02%)		(from 6 fewer to 2	
										more)	

805 CI, confidence interval; COVID-19, coronavirus disease 2019; GRADE, Grading of Recommendations, Assessment, Development and

806 Evaluations; NR, nonrandomized studies; RoB, risk of bias; RR, risk ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

- ^aRisk of bias in Breznik 2023 (40) and Chico-Sanchez 2022 (59).
- 808 $^{b}I^{2}=94.4\%$, $\chi^{2}=372.77$, p(Q)<0.0001, considerable heterogeneity.
- 809 °Outcome definitions rather heterogeneous (test-positive cases and symptomatic cases).
- ^dIn Chico-Sanchez 2022 (59), Starrfelt 2022 (57), and Weng 2023 (50), conversion approach results in wider 95% CI.
- 811 ^eLower grading due to imprecision and indirectness due to varying outcome definitions (symptomatic and not further described COVID-19
- 812 infection)
- 813 $^{f}I^{2}=75.1\%$, $\chi^{2}=16.06$, p(Q)<0.0001, considerable heterogeneity.
- ^gIn Butt 2022 (42) and Kissling 2022 (61), wide 95% CI due to low number of events.
- ⁸¹⁵ ^hLower grading due to imprecision. Type 3 due to nonrandomized studies.
- ⁱRisk of bias in Lytras 2022 (54) and Moline 2021 (45).
- 817 $^{j}I^{2}=78.3\%$, $\chi^{2}=50.58$, p(Q)<0.0001, considerable heterogeneity.
- ⁸¹⁸ ^kOutcome definitions rather heterogeneous (defined as severe infection, hospitalization or death).
- ¹In Moline 2021 (45), conversion approach results in wider 95% CI.
- ^mLower grading due to imprecision and indirectness due to varying outcome definitions (severe infection, defined as such, or hospitalization or
 death)
- ⁿRisk of bias in Moline 2021 (45).
- 823 °I²=85.4%, χ^2 =48, p(Q)<0.0001, considerable heterogeneity.
- ⁸²⁴ ^pNo indirect comparisons, outcome definitions in line.
- ^qRisk of bias in Lytras 2022 (54).

- 826 $^{r}I^{2}=0\%$, $\chi^{2}=4.75$, p(Q)=0.58, no issues of heterogeneity and inconsistency.
- ⁸²⁷ ^sIn Butt 2022 (42), 0 events in both arms, therefore continuity correction of 0.5 necessary. This results in wide 95% CI.

828 **Table 3. Summary of GRADE findings by population subgroup.**

			Certainty	assessment			mRNA-1273,	BNT162b2,	Effect,	Effect, absolute	
Study, n	Study design	RoB	Inconsistency	Indirectness	Imprecision	Other considerations	n/N (%)	n/N (%)	relative (95% CI)	(95% CI)	Certainty
SARS-CoV-2 i	nfection										
$Age \ge 65 y$											
10	NR	Not serious	Serious ^a	Serious ^b	Very serious ^c	Strong association	4647/	8816/	RR 0.74	216 fewer per	Type 4 ^d
							1,236,592	1,728,607	(0.62–0.88)	100,000	
							(0.38%)	(0.51%)		(from 333 fewer to	
										100 fewer)	
Received 3 vac	cine doses				•				•		•
7	NR	Serious ^e	Serious ^f	Serious ^b	Very serious ^g	Strong association	4071/	5302/	RR 0.64	1098 fewer per	Type 4 ^d
							363,053	415,160	(0.54–0.74)	100,000	
							(1.12%)	(1.28%)		(from 1535 fewer to	
										661 fewer)	
Symptomatic S	SARS-CoV-	-2 infection									
$Age \ge 65 y$											
2	NR	Not serious	Serious ^h	Not serious	Not serious	Strong association	967/	1402/	RR 0.74	3030 fewer per	Type 4 ⁱ
							103,629	88,476	(0.56–0.97)	100,000	
							(0.93%)	(1.58%)		(from 8,844 fewer	
										to 2,784 more)	
Received 3 vac	cine doses										
3	NR	Not serious	Serious ^j	Not serious	Serious ^k	Strong association	1145/	1431/	RR 0.74	114 fewer per	Type 4 ⁱ
							261,575	322,830	(0.61-0.90)	100,000	
							(0.44%)	(0.44%)		(from 338 fewer to	
										111 more)	
Severe SARS-	CoV-2 Infe	ction				I	<u> </u>				
$Age \ge 65 y$											
8	NR	Serious ¹	Serious ^m	Serious ⁿ	Very serious ^o	Strong association	646/	1368/	RR 0.65	24 fewer per	Type 4 ^p
							1,333,334	1,812,860	(0.51–0.83)	100,000	
							(0.05%)	(0.08%)			

			Certainty	assessment			mRNA-1273,	BNT162b2,	Effect,	Effect, absolute	
Study, n	Study design	RoB	Inconsistency	Indirectness	Imprecision	Other considerations	n/N (%)	n/N (%)	relative (95% CI)	(95% CI)	Certainty
										(from 41 fewer to 7	
										fewer)	
Received 3 vacc	cine doses	•	.	•	•	•	•				
4	NR	Not serious	Not serious ^q	Serious ⁿ	Serious ^k	Strong association	177/261,262	261/322,329	RR 0.62	10 fewer per	Type 4 ^r
							(0.07%)	(0.08%)	(0.44–0.88)	100,000	
										(from 16 fewer to 3	
										fewer)	
Hospitalization	n due to CO	VID-19									
$Age \ge 65 y$											
7	NR	Serious ¹	Serious ^s	Not serious ^t	Serious ^g	Strong association	651/	1151/	RR 0.69	82 fewer per	Type 3 ^u
							1,197,347	1,161,112	(0.53–0.89)	100,000	
							(0.05%)	(0.10%)		(from 134 fewer to	
										29 fewer)	
Received 3 vacc	cine doses										
3	NR	Not serious	Serious ^v	Not serious ^t	Serious ^w	Strong association	43/	90/	RR 0.55	11 fewer per	Type 4 ^x
							204,278	281,978	(0.37–0.82)	100,000	
							(0.02%)	(0.03%)		(from 18 fewer to 3	
										fewer)	
Death due to C	COVID-19										
$Age \ge 65 y$											
4	NR	Not serious	Not serious ^y	Not serious ^t	Very serious ^z	Strong association	37/	292/	RR 0.72	11 fewer per	Type 4 ^x
							226,581	760,664	(0.54–0.98)	100,000	
							(0.02%)	(0.04%)		(from 19 fewer to 4	
										fewer)	
Received 3 vacc	cine doses			I						1	
2	NR	Not serious	Not serious ^{aa}	Not serious ^t	Very serious ^{bb}	None	0.5/	0.5/	RR 1.01	0.10 fewer per	Type 4 ^x
							158,994	236,694	(0.64–1.57)	100,000	
							(0%)	(0%)		(from 0.93 fewer to	
										1.13 more)	

- 829 CI, confidence interval; COVID-19, coronavirus disease 2019; GRADE, Grading of Recommendations, Assessment, Development and
- 830 Evaluations; NR, nonrandomized studies; R, randomized studies; RoB, risk of bias; RR, risk ratio; SARS-CoV-2, severe acute respiratory
- 831 syndrome coronavirus 2.
- 832 ${}^{a}I^{2}=89.5\%$, $\chi^{2}=85.96$, p(Q)<0.0001, considerable heterogeneity.
- ⁸³³ ^bOutcome definitions rather heterogeneous (test-positive cases and symptomatic cases).
- ⁸³⁴ ^cIn Weng 2023 (50), conversion approach results in wider 95% CI.
- ⁸³⁵ ^dLower grading due to imprecision and indirectness due to varying outcome definitions (symptomatic and not further described COVID-19

836 infection).

- eRisk of bias in Breznik 2023 (40).
- 838 $^{f}I^{2}=80.8\%$, $\chi^{2}=31.26$, p(Q)<0.0001, considerable heterogeneity.
- ^gIn Starrfelt 2022 (57), conversion approach results in wider 95% CI.
- 840 ${}^{h}I^{2}=90.8\%$, $\chi^{2}=10.87$, p(Q)<0.0001, considerable heterogeneity.
- ⁱType 4 due to nonrandomized studies and limited evidence.
- 842 ${}^{j}I^{2}=79.0\%$, $\chi^{2}=9.53$, p(Q)=0.01, considerable heterogeneity.
- ⁸⁴³ ^kIn Butt 2022 (42), low number of events results in wider 95% CI.
- ¹Risk of bias in Moline 2021 (45).
- 845 ^mI²=63.5%, χ^2 =19.17, p(Q)=0.01, substantial heterogeneity.
- ⁸⁴⁶ ⁿOutcome definitions rather heterogeneous (defined as severe infection, hospitalization or death).
- ⁸⁴⁷ ^oIn Moline 2021 (45), wide 95% CI due to conversion approach.

- ^pLower grading due to imprecision and indirectness due to varying outcome definitions (severe infection, defined as such, or hospitalization or
 death)
- 850 $^{q}I^{2}=60.4\%$, $\chi^{2}=7.57$, p(Q)=0.06, substantial heterogeneity.
- ⁸⁵¹ ^rLower grading due to limited evidence, imprecision and indirectness due to varying outcome definitions (severe infection, defined as such, or
- 852 hospitalization or death)
- 853 sI²=72.0%, χ^2 =21.42, p(Q)<0.0001, substantial heterogeneity.
- ⁸⁵⁴ ^tNo indirect comparisons, outcome definitions in line.
- ⁸⁵⁵ ^uLower grading due to imprecision and inconsistency.
- 856 $^{v}I^{2}=47.5\%$, $\chi^{2}=3.81$, p(Q)=0.15, moderate heterogeneity.
- ^wIn Butt 2022, there were only 2 events in the mRNA-1273 arm, resulting in wide 95% CI.
- 858 ^xLower grading due to imprecision and limited evidence.
- $^{y}I^{2}=10.9\%$, $\chi^{2}=3.37$, p(Q)=0.34, no issues of heterogeneity and inconsistency.
- ^zIn Lin 2022 (51), wide 95% CI due to conversion approach.
- 861 ^{aa}I²=0%, χ^2 =0.04, p(Q)=0.84; no issues of heterogeneity and inconsistency.
- ^{bb}In Butt 2022 (42), 0 events in Spikevax and Comirnaty arms, therefore continuity correction adding 0.5 was necessary, resulting in wide 95%
- 863 CI.
- 864

865 **FIGURE LEGENDS**

Figure 1. PRISMA flow diagram. ^aDatabases searched include ICTRP, EMBASE,
EuropePMC, medRxiv, Web of Science, ProQuest Central, Academic Search Complete,
Scopus, and COVIDWHO. ^b16 recently published SLRs and internal documents from
Moderna, Inc were cross-checked. ^cOne study (39) was excluded from the network metaanalysis because the presented data were not comparable to the data from other studies. SLR,
systematic literature review.

Figure 2. Summary of meta-analysis results on clinical effectiveness outcomes of the
 mRNA-1273 versus BNT162b2 COVID-19 vaccines in the overall population of older
 adults aged ≥50 years.

Figure 3. Meta-analysis results comparing the mRNA-1273 versus BNT162b2 COVID-

19 vaccines in the overall population of older adults aged \geq 50 years by study for (A)

877 SARS-CoV-2 infection; (B) laboratory-confirmed symptomatic SARS-CoV-2 infection;


878 (C) severe SARS-CoV-2 infection; (D) hospitalization due to COVID-19; and (E) death

879 **due to COVID-19.**


Figure 4. Summary of sensitivity meta-analyses on clinical effectiveness outcomes of the
mRNA-1273 versus BNT162b2 COVID-19 vaccines (A) using the second order
methodological approach^a and in subgroups of (B) older adults aged ≥65 years; and (C)
older adults aged ≥50 years who received exclusively 3 doses. ^aResults of the second-order
methodological approach for the outcome of symptomatic infection are not presented because
the results are identical to the results of the main analysis (no conversion was necessary for
this outcome in the main analysis).

888 FIGURES

889 Figure 1. PRISMA flow diagram.



- 891 Figure 2. Summary of meta-analysis results on clinical effectiveness outcomes of the
- 892 mRNA-1273 versus BNT162b2 COVID-19 vaccines in the overall population of older



893 adults aged \geq 50 years.

895 Figure 3. Meta-analysis results comparing the mRNA-1273 versus BNT162b2 COVID-

896 **19 vaccines in the overall population of older adults aged** \geq **50 years by study for (A)**

897 SARS-CoV-2 infection; (B) laboratory-confirmed symptomatic SARS-CoV-2 infection;

898 (C) severe SARS-CoV-2 infection; (D) hospitalization due to COVID-19; and (E) death

899 **due to COVID-19.**

900 (A)

Study (nRCTs)	mRNA-1273 n/N	BNT162b2 n/N			Age	Weight	Random Effects Risk Ratio [95% CI]
Braeye 2023	41/1155	243/13613		⊢ ∎-1	65-85 years	4.63%	1.99 [1.44, 2.75]
Breznik 2023	47/420	116/478	⊢⊷⊣		50+ years	4.76%	0.46 [0.34, 0.63]
Butt 2022	17/158993	68/236693	⊢_ ∎]		50+ years	2.88%	0.37 [0.22, 0.63]
Chemaitelly 2022	297/79456	474/180790		H=-1	50+ years	6.52%	1.43 [1.23, 1.65]
Grewal 2022	3089/57604	4059/48706			60+ years	7.17%	0.64 [0.62, 0.67]
Hatfield 2022	6/466	22/1196	⊢ −−		50+ years	1.37%	0.70 [0.29, 1.72]
Kelly 2022	654/100751	644/83998	H#4		65+ years	6.82%	0.85 [0.76, 0.94]
Kissling 2022	20/263	375/2949	⊢⊷		60+ years	3.63%	0.60 [0.39, 0.92]
Martinez-Baz 2021	20/215	327/2109	⊢ ⊷⊣		60+ years	3.65%	0.60 [0.39, 0.92]
Nguyen 2023	264/45285	415/45285	H=+1		65+ years	6.44%	0.64 [0.55, 0.74]
Puranik 2023	463/4105	1174/7119	ы		55+ years	6.88%	0.68 [0.62, 0.76]
Rosenberg 2022	5977/1614377	10827/1793696			50+ years	7.21%	0.61 [0.59, 0.63]
Thompson 2021	95/6374	163/8500	⊢ •		50+ years	5.42%	0.78 [0.60, 1.00]
van Ewijk 2022	10/273	243/2542	⊢ 1		50+ years	2.37%	0.38 [0.21, 0.71]
Voko 2022a	122/116247	1918/845906	H=H		55+ years	6.15%	0.46 [0.39, 0.56]
Bello Chavolla 2023	NA/NA	NA/NA	⊢ •–-1		60+ years	2.68%	0.49 [0.28, 0.86]
Chico Sanchez 2022	NA/NA	NA/NA		⊢∎	60+ years	0.88%	4.98 [1.55, 15.97]
Lin 2022	NA/NA	NA/NA			50+ years	7.17%	0.88 [0.84, 0.92]
Robles-Fontan 2022	NA/NA	NA/NA	н		55+ years	6.99%	0.69 [0.63, 0.75]
Starrfelt 2022	NA/NA	NA/NA	⊢ ■		65+ years	1.29%	0.74 [0.29, 1.87]
Voko 2022	NA/NA	NA/NA	⊢ •-1		65+ years	4.59%	0.66 [0.48, 0.92]
Weng 2023	NA/NA	NA/NA	F	1	65+ years	0.50%	0.74 (0.15, 3.60]
Total SARS-CoV-2 infe Heterogeneity: Chi ² =3 Test for overall effect:	72.77, df=21 (P=0), l ⁱ	A-1273), 21068 (BNT162 ² =94.4%	b2)			100%	0.72 [0.64, 0.80]
	Г		1		I	1	
	0	(1 Itio (log scale)	10 10	00	1000
		Environ en			DNT46252		
		Favors mi	KNA-12/3	Favors	BNT162b2		

902

903 **(B**)

Study (nRCTs)	mRNA-1273 n/N	BNT162b2 n/N			Age	Weight	Random Effects Risk Ratio [95% CI]
Butt 2022	17/158993	68/236693	L	1	50+ years	5.85%	0.37 [0.22, 0.63]
Grewal 2022	474/1831	719/2139		⊦∎-1	60+ years	29.05%	0.77 [0.70, 0.85]
Kelly 2022	654/100751	644/83998		· = ·		28.15%	0.85 [0.76, 0.94]
Kissling 2022	20/263	375/2949	F		60+ years	8.13%	0.60 [0.39, 0.92]
Puranik 2023	463/4105	1174/7119		⊦ ∎-1	55+ years	28.82%	0.68 [0.62, 0.76]
	SARS-CoV-2 infections: i ² =16.06, df=4 (P=0), l ² =7 ect: Z=–4.6 (P=0)		0 (BNT162b2)	•		100%	0.72 [0.62, 0.83]
		0.1		1			
				Risk Ratio	(log scale)		

Favors mRNA-1273

Favors BNT162b2

904

905

(**C**)

Study (nRCTs)	mRNA-1273 n/N	BNT162b2 n/N		Age	Weight	Random Effects Risk Ratio [95% CI]
Butt 2022	2/158993	21/236693	F	50+ years	1.18%	0.14 [0.03, 0.60]
Grewal 2022	161/1518	218/1638	I=I	60+ years	15.55%	0.80 [0.66, 0.96]
Kelly 2022	14/100751	22/83998	⊢ ∎-1	65+ years	4.53%	0.53 [0.27, 1.04]
Robles-Fontan 2022	183/402102	296/453015	H	55+ years	15.80%	0.70 [0.58, 0.84]
Rosenberg 2022	646/1614377	1195/1793698	M	50+ years	18.56%	0.60 [0.55, 0.66]
Voko 2022a	24/116251	273/845906	F+4	55+ years	8.59%	0.64 [0.42, 0.97]
Bello Chavolla 2023	NA/NA	NA/NA	FI	60+ years	1.74%	0.71 [0.22, 2.29]
Lin 2022	NA/NA	NA/NA		50+ years	19.52%	0.83 [0.80, 0.87]
Lytras 2022	NA/NA	NA/NA	F	60-79 years	1.30%	0.27 [0.07, 1.07]
Moline 2021	NA/NA	NA/NA	F	65+ years	0.13%	0.65 [0.01, 57.27]
Starrfelt 2022	NA/NA	NA/NA	⊢_ •1	65+ years	1.62%	0.38 [0.11, 1 .28]
Voko 2022	NA/NA	NA/NA	⊦≠I	65+ years	11.47%	0.62 [0.45, 0.85]
Total severe SARS-Co Heterogeneity: Chi ² =5 Test for overall effect:	0.58, df=11 (P=0), I ²		BNT162b2) ♦		100%	0.67 [0.57, 0.78]
			0 0.1 1 10	100 1000		
			Risk Ratio (log scale	,		
		Fa	ivors mRNA-1273	Favors BNT162b2		

906

908 **(D**)

Study (nRCTs)	mRNA-1273 n/N	BNT162b2 n/N			Age	Weight	Random Effects Risk Ratio [95% Cl]	
Butt 2022	2/158993	21/236693	├── ■──_1		50+ years	1.75%	0.14 [0.03, 0.60]	
Nguyen 2023	41/45285	69/45285	⊦ ∎-1		65+ years	12.75%	0.59 [0.40, 0.87]	
Robles-Fontan 2022	183/402102	296/453015	I=1		55+ years	20.24%	0.70 [0.58, 0.84]	
Rosenberg 2022	646/1614377	1195/1793698	н		50+ years	23.17%	0.60 [0.55, 0.66]	
Lin 2022	NA/NA	NA/NA	-		50+ years	24.15%	0.83 [0.80, 0.87]	
Moline 2021	NA/NA	NA/NA	F	1	65+ years	0.20%	0.65 [0.01, 57.27]	
Starrfelt 2022	NA/NA	NA/NA	⊢_ ∎1		65+ years	2.40%	0.38 [0.11, 1.28]	
Voko 2022	NA/NA	NA/NA	F≢4		65+ years	15.33%	0.62 [0.45, 0.85]	
Total hospitalizations of Heterogeneity: Chi ² =4 Test for overall effect:	8, df=7 (P=0), I ² =85.	'2 (mRNA-1273), 1581 (4%	BNT162b2)			100%	0.65 [0.53, 0.79]	
		1 (0 0.1 1	10 1	DO 1000			
	Risk Ratio (log scale)							
		Fav	ors mRNA-1273	Favo	rs BNT162b2			


909

910

(E)

mRNA-1273 n/N	BNT162b2 n/N		Age	Weight	Random Effects Risk Ratio [95% CI]
0.5/158994	0.5/236694	F	50+ years	0.31%	1.49 [0.03, 75.03]
57/402102	72/453015	F ⊞ -1	55+ years	39.60%	0.89 [0.63, 1.26]
24/116247	273/845906	F-∰-8	55+ years	27.46%	0.64 [0.42, 0.97]
NA/NA	NA/NA	FB1	60+ years	3.45%	0.71 [0.22, 2.29]
NA/NA	NA/NA	F	65+ years	2.01%	0.70 [0.15, 3.25]
NA/NA	NA/NA	F	60-79 years	3.51%	0.33 [0.10, 1.07]
NA/NA	NA/NA	F ₩ -1	65+ years	23.66%	1.00 [0.64, 1.57]
		2)		100%	0.80 [0.64, 0.99]
	0	0.1 1 10 Bick Batic (log coale)	100 100	D	
	n/N 0.5/158994 57/402102 24/116247 NA/NA NA/NA NA/NA NA/NA VID-19: 81.5 (mRN/ 75, df=6 (P=0.58), I ²	n/N n/N 0.5/158994 0.5/236694 57/402102 72/453015 24/116247 273/845906 NA/NA NA/NA NA/NA NA/NA NA/NA NA/NA NA/NA NA/NA VID-19: 81.5 (mRNA-1273), 345.5 (BNT162b 75, df=6 (P=0.58), P=0% =2.01 (P=0.0441)	n/N n/N 0.5/158994 0.5/236694 57/402102 72/453015 H=H 24/116247 273/845906 H=H NA/NA NA/NA H=H NA/NA H NA/NA H=H NA/NA H NA/NA H=H NA/NA H NA/NA H N	n/N n/N Age 0.5/158994 0.5/236694	n/N n/N Age Weight 0.5/158994 0.5/236694 - 1 50+ years 0.31% 57/402102 72/453015 H - 55+ years 39.60% 24/116247 273/845906 H - 55+ years 27.46% NA/NA NA/NA Image: Comparison of the second of the


- 912 Figure 4. Summary of sensitivity meta-analyses on clinical effectiveness outcomes of the
- 913 mRNA-1273 versus BNT162b2 COVID-19 vaccines (A) using the second order
- 914 methodological approach^a and in subgroups of (B) older adults aged \geq 65 years; and (C)
- 915 older adults aged \geq 50 years who received exclusively three doses. ^aResults of the second-
- 916 order methodological approach for the outcome of laboratory-confirmed symptomatic
- 917 infection are not presented because the results are identical to the results of the main analysis
- 918 (no conversion was necessary for this outcome in the main analysis).



919 (A) Second order methodological approach

920

921 (B) Older adults aged ≥ 65 years





924 (C) Older adults aged \geq 50 years who received exclusively three doses

